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Non-coding RNAs (ncRNAs) account for a higher percent of the genome than coding 
mRNAs, and are implicated in human disease such as cancer, neurological, cardiac and many 
others. While the majority of ncRNAs involved in disease were originally attributed to a class of 
RNAs called micro RNAs (miRNAs) with a small size of only about 19 -24 base pairs, emerging 
research has now demonstrated a class of long non-coding RNAs (lncRNAs) that have a size of 
over 200 base pairs to be responsible for gene regulation and other functional roles and have also 
found to contribute to pathogenesis in humans. The increased size and structural complexity 
require novel tools to study their interactions beyond RNA interference. Synthetic antibodies are 
classic tools and therapeutics utilized to study and treat proteins involved in human disease. 
Likewise we hypothesize that structured RNAs can also take advantage of synthetic antibodies to 
probe their functions and be utilized as therapeutics. 
 Currently, antibodies have been raised against microbial riboswitches and other 
structured RNAs of single-celled organisms, and only one human structured RNA to the best of 
our knowledge. However, no one has yet to create a synthetic antibody capable of behaving as a 
therapeutic against a structured RNA. We therefore sought to raise an antibody Fab against a 
structured RNA, human initiator tRNA, a model oncogenic non-coding RNA and demonstrate its 
efficacy in vitro. We then characterized the antibody and explored delivery options in cancer 
cells including the use of nanoparticle delivery systems. With the emerging transcriptome 
revealing new ncRNAs implicated in human disease, our research has begun to address a new 
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CHAPTER 1: INTRODUCTION 
 In the current college introductory level biology textbooks, the central dogma of 
molecular biology is taught where DNA is transcribed into RNA which in turn is translated into 
protein.1 It also teaches of only three types of RNAs in detail, mRNA as the coding message 
transcribed from DNA, ribosomal RNA which combined with ribosomal proteins produces the 
ribosome, the site of protein translation, and tRNA to transfer amino acids to the growing 
polypeptide chain until the protein is completed and liberated from the ribosome.1 In some 
textbooks, few non-coding RNAs are briefly mentioned. 
 After the sequencing of the human genome in April of 2003 by competing scientists 
Craig Venter and Francis Collins2, there were surprisingly few protein coding genes where it was 
expected that the more complex the organism, the more coding genes it should have.3 However 
this initial assumption was far from correct. We now know of thousands of non-coding RNAs 
(ncRNAs), and still more being discovered are indeed transcribed from the DNA message. These 
include snoRNAs, miRNAs, siRNAs, snRNAs, exRNAs, piRNAs, and long non-coding RNAs 
(lncRNAs) which provide novel functions.4-7 Indeed the majority of the genome is transcribed 
but does not code for proteins. 
 While RNA only differs from DNA chemically at the 2' ribosyl carbon having a hydroxyl 
functional group, these two polymers take on completely different structures and functions. DNA 
is always double stranded (except in some viruses), is highly stable, and forms a double helix.1 
Its sole purpose is to store information but lacks any function with the exception of artificially 
created DNA enzymes (DNAzymes).8 RNA on the other hand is single stranded, less stable, and 
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can adopt many secondary and tertiary conformations.9 Functionally, it can perform many roles 
including structural support, enzymatic catalysis (ribozymes)10, gene regulation and many 
functions that are also associated with proteins.11 Indeed, the fact that RNA can partake in 
cellular functions and retain genetic information has formed the hypothesis of an RNA world as 
the predecessor of all life on Earth.11 
 Molecular biology is a relatively new field and with it comes paradigm shifts as new 
discoveries are made. For example, it was long thought that proteins were most likely the genetic 
material since they were the most complex and abundant macromolecule in the cell until Alfred 
Hershey and Martha Chase performed their famous blender experiment demonstrating that DNA 
was in fact the material of inheritance.1,2,12 Much like we thought that proteins were the main 
functional components of cells and their aberrance leading to disease13, a new paradigm shift has 
occurred. We now know that RNAs perform many of the same kinds of important functions as 
their protein counterparts and even contribute to human disease by various mechanisms.4,13 
 Indeed, about 2/3 of the mammalian genome is transcribed and functional roles are 
beginning to be assigned to these transcripts.14 Non-coding RNAs can be roughly categorized 
into short, mid-size, and long ncRNAs, with multiple specific categories within.4 The micro 
RNAs (miRNAs) in particular, part of the short RNA class with a size of about 19-24 base pairs 
(bp) have acquired the greatest amount of attention due to their high level of involvement in 
various cancers and a myriad of other diseases such as Crohn’s disease, Alzheimer’s disease and 
Down’s Syndrome.4,13,15 Their small size permits both their study and therapeutic design based 
on antisense oligonucleotides (ASOs) which function by base pairing to the target miRNA and 
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neutralizing their function in cases where overexpression of the target miRNA is promoting the 
disease.4 
Over the last few years however, the lncRNAs which are roughly defined as transcripts 
that are greater than 200 bp11,13,16 in size, have begun to receive increasing attention due to their 
normal biological roles in cell differentiation, organism development, and ability to effect 
epigenetic changes through chromatin remodeling in addition to their involvement in cancer, 
neurological diseases and other human pathologies when misregulated.4,13 The lncRNAs are also 
able to regulate transcription and post-transcriptional processes and new regulatory functions are 
continuously being discovered.4,11,16 Many lncRNAs are antisense transcripts of coding and other 
non-coding lncRNAs and they can function in cis or trans (and in some cases both).17 There are 
three main classes of lncRNAs, lincRNAs, T-UCRs, and others that don’t fit well into either of 
the first two categories.4 
T-UCRs as its name suggests, are transcripts of ultra-conserved regions that have 
remained relatively unchanged in higher order vertebrates and are completely conserved in 
humans and rodents.4,16 They appear to be important for brain development where they are in 
close proximity, overlapping, or antisense to protein coding genes involved in crucial 
developmental regulatory processes where they can likely perform regulatory effects on these 
proteins.11,13,16 As such, these conserved transcripts probably played an important role in 
vertebrate evolution and are in all likelihood critical for normal development.16 
LincRNAs are intergenic transcripts that often regulate the genes within their proximity 
but may also cause a cascade of effects that promote regulation at distal sites.4 Among the most 
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famous is Hox transcript antisense RNA (HOTAIR), due to its well understood role in human 
cancers including metastatic breast cancer.18 HOTAIR functions by interacting with proteins that 
promotes chromatin remodeling which alters gene expression at affected loci. Specifically, 
HOTAIR recruits the Polycomb repressive complex (PRC2) from its 5’ end and interacts with 
histone lysine-specific demethylase 1 (LSD1) at its 3’ end with the resulting effect of silencing 
the homeobox D (HOXD) locus on human chromosome 2.19 HOTAIR itself is an antisense 
transcript of the homeobox C (HOXC) locus expressed on human chromosome 12 but is 
transported by the Suz-Twelve protein to function in trans.19 By using its sequence to guide 
PRC2 to target specific loci, HOTAIR promotes silencing of tumor suppressor genes through 
epigenetic modification with overexpression leading to tumorigenesis.4,18 
Other lncRNAs are also highly involved in chromatin remodeling and are capable of 
recruiting PRC2. X-inactivate specific transcript (XIST) for example is a lncRNA responsible for 
initiating X-inactivation in female mammals and does so by recruiting PRC2 to the X 
chromosome from which it is transcribed promoting the formation of repressive 
heterochromatin.20 Unlike HOTAIR which works in trans, XIST works in cis to inactivate the 
chromosome copy from which it is transcribed.16 Interestingly, XIST is regulated by other lnc-
RNAs such as JPX which works as an activator, and antagonistically by its antisense RNA 
TSIX.21 Disruption of either the XIST or TSIX transcripts in mice was found to be embryonic 
lethal in female animals16 and aberrant expression of XIST has been identified in some human 
cancers.16,20 The fact that XIST can inactivate an entire chromosome and its aberrant expression 




The emerging concept derived from the above mentioned lncRNAs is that they are 
capable of providing sequence specificity and directing PRC2 and other chromatin modifying 
proteins to perform epigenetic changes that alter gene expression on a global expression level, 
thereby capable of silencing not just one or two genes but an entire loci simultaneously. While 
microRNAs are more specialized in their regulatory functions and their aberrance can lead to 
human disease, lncRNAs effectively are capable of a higher level of control and responsibility 
that when gone awry as in the case of HOTAIR leads to a higher degree of deleterious effects 
such as promoting metastatic cancer.4 With over 3,000 antisense transcripts having been 
discovered to associate with PRC222 it is highly likely although not yet characterized, that these 
transcripts play similar regulatory roles and their aberrance leading to human disease or outright 
embryonic lethal thus their continued study is significantly warranted17. 
In addition, other lncRNAs that do not interact with PRC2 were also found upregulated in 
human cancers such as antisense lncRNA of the INK4 locus (ANRIL) which represses the 
INK4b/ARF/INK4a tumor suppressor gene locus23 and metastasis-associated in lung 
adenocarcinoma transcript (MALAT-1) which normally assists in regulating alternative exon 
splicing by interacting with serine/arginine rich (SR) proteins and increased expression has been 
associated with metastatic lung cancers for which it was named.13,24 Therefore lncRNA 
upregulation appears to promote tumorigenesis and the ability to mute their expression should 
lead to improved prognosis. 
While overexpressed miRNAs can be studied and silenced with ASOs, this technique is 
significantly more challenging with lncRNAs since they contain complex secondary and tertiary 
structures including double stem-loop domains, masking potential binding sites.9 Furthermore, 
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lncRNAs can be very large in size, with many in the several kilobase range and often contain 
multiple functional domains in which to interact with multiple protein partners.7 Thus outright 
knockout of expression of the entire noncoding transcript in some instances could have 
undesirable consequences, though with HOTAIR, silencing with small interfering RNA (siRNA) 
or gene knockout was shown to reduce tumor growth in a mouse xenograft model.25 To further 
complicate the matter, some ncRNAs overlap directly or are intronic with coding and other non-
coding genes.17 
Currently lncRNA structure is poorly understood with most of our knowledge derived 
from computational analysis comparing free energy stability via thermodynamic modeling, 
covariation methods when similar structures are already known, and by experimental mapping 
such as with various RNA footprinting techniques that reveal exposed residues and 
strandedness.9 Specifically, selective 2'-hydroxyl acylation analyzed by primer extension 
(SHAPE) is a powerful footprinting technique that can probe for secondary structure by a 
combination of chemical modification to more available residues and reverse transcriptase 
polymerase chain reaction (RT-PCR) to label generated fragments which are then identified by 
either gel electrophoresis of capillary sequencing and their corresponding software analysis 
tools.9 However, most of these techniques do not provide significant or any information on 
tertiary structure which cannot be detected from sequence alone. At the time of this writing, no 
one has yet to publish any information on the tertiary structure of any mammalian lncRNAs. 
Notwithstanding, lncRNAs are more protein-like in nature than the other non-coding 
functional RNAs and as such we hypothesize that they can be studied and be targeted 
therapeutically more like proteins. X-ray crystallography is generally the most accepted method 
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for determining protein structure either as a stand-alone structure or with its binding partners as 
some proteins may alter conformation upon binding.26 Recently, the development of chaperone-
assisted RNA crystallography (CARC) was developed to address the difficulty in crystalizing 
structured RNAs.27 For this method, an antibody in the form of an antigen binding fragment 
(FAB) was selected from a phage library that tightly binds to the target RNA antigen. The 
antigen, C209 P4-P6 domain derived from the Tetrahymena group I intron was then co-
crystalized with the selected Fab to yield a crystal with a resolution of 1.95Å.27 CARC likely 
owes its advantage due to crystal contact formation and enhanced phasing information. Although 
this technology has not yet been applied to mammalian structured RNAs, it is likely that the 
tertiary structure of lncRNA transcripts or individual structural domains could also be solved 
using this same technology. 
Antibodies in general have been key biological tools necessary to detect, purify, and 
characterize proteins. Furthermore, they have been more recently implicated as potent 
biotherapeutics with dozens commercially available in the US and Europe and many more in the 
pipeline progressing through clinical trials.28 Due to their high affinity, specificity, and 
selectivity, antibodies provide a great means for targeting diseased tissues and can significantly 
reduce off-target side effects.29-31 However, currently all commercially available therapeutic 
antibodies target protein surface antigens and none target structured RNAs. Since RNA-binding 
antibodies have been demonstrated to bind to structured RNAs of unicellular organisms for other 
purposes, we hypothesize that antibodies can also be developed against structured mammalian 
RNAs that have therapeutic potential filling in an important gap in the antibody targeting field. 
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In order to test this proof-of concept, we chose human initiator methionyl tRNA, 
(tRNAiMet) because it is well characterized including its tertiary structure, it is evolutionarily 
conserved in all vertebrates, and its small size reduces the need to identify smaller functional 
domains.32-34 We also chose tRNAiMet from a functional perspective because of its role in cancer 
where tRNAs in general have been shown to be upregulated and tRNAiMet overexpression was 
shown to promote tumorigenesis.35,36 Since tRNAiMet is part of translation initiation, we 
hypothesis that disrupting its binding to the initiation complex should result in reduced protein 
expression and therefore reduced cell growth particularly in cancers which require higher protein 
production to maintain their rapid growth rate. 
 Additionally most structured RNAs are intracellular including nuclear targets and thus 
require the ability of the therapeutic antibody to enter the cell. Since viruses and other pathogens 
can gain intracellular entry by exploiting receptor mediated endocytosis (RME) in combination 
with other mechanisms, we hypothesize that utilizing similar techniques will allow for successful 
delivery of therapeutic antibodies into cancer cells. 
 New ncRNAs are constantly being discovered through various techniques such as cDNA 
profiling and genome tiling arrays, many likely having important functions and some with 
secondary and tertiary structures.9,11 What was thought to once be simply transcriptional noise 
due to lower expression and the sensitivity of the techniques being utilized, it is now apparent 
that the vast majority of the human genome is transcribed with the non-protein coding genes way 
outnumbering the coding ones, and that these transcripts play many important roles.7,11 Likewise, 
classification of ncRNAs continues to change reflecting the increasingly growing 
knowledgebase. As such, new tools are needed to understand the structure and function of these 
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ncRNAs and the ability to target them with therapeutics antibodies will increase in demand as 
many of them have already been shown to be upregulated in human disease. During our work in 
progress, only one other researcher has successfully made an antibody against an RNA involved 
in human disease although its therapeutic potential has not been characterized.37 Thus there is a 
significant deficit in RNA-targeting antibodies where we predict that in the future there will be 
an antibody for every structured RNA just as there is for proteins and other biomolecules of 
interest. Our research is laying the foundation to understand the rules for developing successful 
RNA binding antibodies that have therapeutic potential as well as the ability to deliver them 
intracellularly. The journey has only begun. 
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CHAPTER 2: SELECTION OF A FUNCTIONAL RNA BINDING FAB 
FROM THE YSGR MIN LIBRARY UTILIZING HUMAN INITIATOR 
TRNA AS A MODEL SYSTEM 
Introduction 
 Non-coding RNAs play an important role in regulating intracellular activities.1,2 Like 
proteins, they can perform various functions such as gene regulation and enzymatic catalysis. 
Non-coding RNAs often adopt specific tertiary structures that can act as structural scaffolds for 
ribonucleoprotein complex formation, alter their conformation upon binding cofactors for gene 
regulation, or participate directly in enzymatic activities.3,4 Many non-coding structured RNAs 
are involved in human disease including cardiovascular, neurological, and cancer.5 As such 
studying their interactions with macromolecules and other molecular entities would allow for 
rational therapeutic design to combat these debilitating disorders.  
 Some non-coding RNAs when over-expressed can directly lead to oncogenesis.6 Not 
surprisingly, the tRNAs, important structured non-coding RNAs involved in protein synthesis, 
have been shown to be upregulated in several cancers.7 Specifically, over-expression of initiator 
tRNA (tRNAiMet) in human breast epithelial cell lines showed increased cell metabolic activities 
and cell proliferation.8 Initiator tRNA is unique in that it is the only tRNA utilized during the 
initiation step of protein synthesis and is obligate to form the translation pre-initiation 
complex.9,10 Once charged with methionine, it binds to initiation factor 2 along with GTP 
forming a ternary complex which begins the assembly process of the complete translation 
initiation complex.9,10 Therefore, a reduction of tRNAiMet would be expected to disrupt protein 
synthesis. Protein synthesis is known to be upregulated in cancer which permits rapid growth.11 
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Therefore we can hypothesize that reduction of intracellular tRNAiMet should lead to a reduction 
in cancer cell growth via disruption of protein synthesis. 
 However, selective targeting of the structured RNAs is a very challenging task. Current 
RNA targeting methods include small molecules and RNA interference (RNAi), both presenting 
significant challenges.5,12,13 In this work, we set out to use antibodies in the form of Fab 
fragments to target structured non-coding RNAs using tRNAiMet as a model system. 
 Antibodies have been utilized as molecular biology tools since the 1970s.14,15 They have 
been the cornerstone of techniques such as Western blotting, Affinity chromatography, and 
ELISA. More recently, antibodies have been developed as therapeutics bringing in billions of 
dollars in sales each year (44.6 billion globally in 2011).16  For example, Trastuzumab is an 
antibody that has affinity to the Her-2 receptor found upregulated only in breast and certain other 
cancers, which permits selective targeting of tumor cells.17 Currently however, all marketed 
therapeutic antibodies only target proteins. 
 RNA-binding antibodies could be used as research tools for a better understanding of 
RNA structure and function, and may one day also be utilized as therapeutics much like their 
protein counterparts. Specifically, an antibody raised against tRNAiMet would likely inhibit 
protein synthesis by blocking its interactions with other macromolecules required for protein 
synthesis initiation. However, the field is relatively new with only limited numbers (published 
and unpublished results) of RNA-binding antibodies available.18-22  
 Traditional methods of antibody production by injecting antigens into animals and then 
collecting the serum are not possible with structured RNAs. RNases present in the animal would 
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destroy foreign RNAs much faster than the animal could mount an immune response.23 
Furthermore, tRNAiMet is identical in all vertebrates and therefore an immune response mounted 
against the target antigen would not be likely. With the advent of phage display technology, 
humanized monoclonal antibodies, expressed as individual Fabs have made RNA-binding 
antibodies a reality. 
 The RNA antibody field is however still in its infancy. Until recently, all RNA binding 
Fabs came from phage libraries that were designed to target proteins. As such, several of the 
antibodies generated from these libraries demonstrated low binding affinity and required affinity 
maturation to achieve optimal binding to the target RNA antigens.19 Clearly an RNA favored 
phage library was needed and the first of its kind, the YSGR Min library was recently developed 
to address this issue.19 The YSGR Min library yielded RNA-binding antibodies with comparable 
or better affinities and specificities than earlier libraries such as YSGRX. However, due to the 
limited structured RNAs challenged, this library requires further validation as a favorable RNA-
binding library. 
 Thus far, antibodies have been successfully raised against non-coding RNAs primarily 
for the purpose of enhancing crystallization of the RNA. Chaperone-assisted RNA 
crystallography (CARC) has indeed facilitated RNA crystallography by promoting crystal 
contact formation and assisting in phasing.20-22 However, none of these Fabs have been shown to 
have function besides acting as a crystal chaperone and none have been raised against vertebrate 
RNAs. Furthermore, to the best of our knowledge, almost no work has been done in targeting 
vertebrate functional RNAs using antibodies with one exception in which Jung et. al. selected an 
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antibody against BC200 RNA, a structured RNA found in brain tissue, but without 
demonstrating any functional role of the antibody either in vitro or in vivo.24 
 Here we describe the selection and characterization of antibody Fabs against the model 
oncogenic RNA, vertebrate tRNAiMet, and as validation of the YSGR Min library as being 
optimized to bind structured RNAs compared to the control YSGRX library. We also present the 
function of a selected Fab for its ability to inhibit in vitro protein translation. 
Results and Discussion 
Selection and Identification of tRNAiMet Binding Fabs 
Preparation of tRNAiMet 
The sequence of the conserved vertebrate tRNAiMet was constructed from DNA 
oligonucleotides and cloned into DNA plasmids as both the native sequence and with a 29 
nucleotide tag at the 3' end. The tag was chosen to be on the 3' end where methionine would 
normally be attached to permit proper RNA folding and to reduce interference during the 
selection process. Tagging is necessary to immobilize the RNA for the subsequent selection 
process and the untagged native RNA is later used to characterize binding. Plasmids were then 
amplified in JM109 cells, digested, in vitro transcribed and purified. Both tagged and untagged 
versions of tRNAiMet were produced in good yield. In order to immobilize the tagged RNA, a 
complimentary single-stranded DNA with a covalently attached biotin was annealed to the tag. 
Before selection is performed, the RNA is folded by heating it in the presence of magnesium. 
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Selection of tRNAiMet Binding Fabs 
Selection was performed using similar methods to those previously described utilizing 
the YSGR Min library.19 The YSGRX library optimized for binding proteins was also used in the 
selection as a control. These libraries are comprised of M13, a filamentous phage (Ff) that is 
packaged with a single-stranded DNA phagemid as shown in figure 2.1. Each phagemid contains 
a unique Fab sequence fused to the pIII phage surface protein for display with a weak promoter, 
an antibiotic resistance marker, and both an E. coli and phage origin of replication, but lacks the 
remaining phage genes that produce functional phage proteins.25 Both libraries contain the same 
framework Fab sequences but differ in their complimentary determining regions (CDRs) that 
directly interact with the target antigens. The CDRs themselves are limited to the amino acid 
constraints of the library design.19 
 In order to produce new phage particles that display unique Fabs, a helper phage, 
M13KO7, is utilized that contains all of the wild-type phage genes but lacks a Ff functional 
origin of replication. Because the majority of phage proteins including pIII are produced from 
the helper phage genome, statistically the resulting phages will be assembled having only one 
expressed fusion Fab-pIII protein per phage and due to the weak expression of the fusion protein 
almost 90% of the phage population will be assembled without any displayed Fab.25 The purpose 
of using this method is to produce only monovalent phage for display so that only high affinity 
binders rather than high avidity binders will be selected for. 
 For selection with both phage libraries, the biotinylated tagged tRNAiMet was 
immobilized by binding to streptavidin magnetic beads. In the first round, phages are bound to 
the immobilized RNA antigen in the presence of free streptavidin and BSA to remove 
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streptavidin-binding phage particles and general non-specific protein binding phage. After 
binding, the majority of unbound phage particles are washed away and the remaining phage are 
amplified in XL-1 blue cells and re-purified as shown in figure 2.2. 
 In subsequent rounds, free streptavidin is absent and a nucleic acid competitor is 
introduced to remove non-specific nucleic acid binders. Isolated E. coli tRNAs are commonly 
used as nucleic acid competitors but since our target antigen is a tRNA and all tRNAs are 
thought to be similar in structure, we hypothesized that the E. coli tRNAs may inadvertently 
remove the eukaryotic tRNAiMet binding Fabs. Therefore sheared salmon sperm DNA was used 
as a substitute competitor. 
 Furthermore, in subsequent rounds, selection is performed on both the target RNA 
antigen and a mock control where only the streptavidin beads are present. Phage titering is used 
to identify the reduction of phage after selection compared to the input with an ideal reduction 
rate of at least 105 and enrichment which compares the selection output to the control output. As 
subsequent rounds are performed, enrichment increases while phage diversity decreases if 
selection is successful. If high enrichment is observed, many Fab clones could be identified of 
varying affinities. To select for higher affinity binders, stringent conditions can be applied using 
10 fold less of the RNA target concentration and 10 fold more competitor salmon sperm DNA. 
 After selection, both the YSGR Min library and YSGRX control library showed 
enrichment. As seen in table 2.1, enrichment was already observed after the second round which 
increased subsequently over the next two rounds. By the end of round three, enrichment was 
over 2,000 fold. In contrast, the YSGRX library did not show enrichment until after round 4, 
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which was significantly less than observed with YSGR Min at the same round. Since round 3 did 
not demonstrate enrichment, round 4 was repeated to verify the result as shown in table 2.2. 
 Stringent conditions were also performed on YSGR Min beginning at round 3. Both 
rounds 3 and 4 showed enrichment as shown in figure 2.1. Enrichment for stringent rounds 3 and 
4 were lower than that under non-stringent conditions suggesting that lower affinity binders were 
out-competed by the competitive salmon sperm DNA and/or that the lower concentration of 
RNA was below some of the Fabs binding affinity. Stringent conditions were also applied to 
round 4 of YSGRX however no enrichment was observed (data not shown). Thus far, the YSGR 
Min library was shown to be superior for enrichment of Fabs over the YSGRX control library for 
selection. 
Phage ELISA to Identify Fab Sequences 
Phage ELISA was used to analyze the clones from both libraries to identify potential 
binders. Using the YSGRX library, 43/48 clones generated a positive signal with all but 2 
showing a very high absorbance signal. Of these 43 positive clones, 10 clones that generated the 
highest absorbance intensity were selected for sequencing. Sequencing results as shown in table 
2.3, demonstrated that all of the Fab clones were identical. Then 12 more clones were selected 
for sequencing, this time selecting a clone with low signal, and the rest with randomized high 
positive signals to reduce biasing of high expressors. The new sequencing results identified two 
additional unique Fabs with 4 identical Clone 2 sequences and 2 identical Clone 3 sequences. 
However, Clone 1 appeared at the highest frequency and was identified in 2/3 of the ELISA 
screen. The low signal clone was also identified as Clone 1. The higher frequency of Clone 1 
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suggests that it either binds with higher affinity to tRNAiMet than the other clones or that it is 
better expressed than other Fabs.  
 Phage ELISA was performed on clones identified from the output of both rounds 3 and 4 
from the YSGR Min library under stringent conditions.  Of the 10 clones selected for sequencing 
from the 3rd round, 3 unique clones were identified. Clone 4 was identified with the highest 
frequency identified 6 times. Clone 5 was only identified once and clone 6 was identified 3 
times. From the 4th round, both Clone 4 and Clone 6 were re-identified in equal frequency of 
5/11 clones. Clone 5 was not identified in this screen however one new clone, Clone 7 was 
identified.  
Characterization of tRNAiMet Binding Fabs 
Expression of Soluble Fabs and EMSA 
In order to produce soluble Fabs that are not attached to the phage pIII protein, Kunkel 
mutagenesis was performed on clones 1-7 to introduce an amber stop codon. The Kunkel 
products were electroporated into 34B8 cells and all Fabs were able to express soluble proteins 
except for clone 5. The remaining 6 Fab proteins were purified by protein A affinity 
chromatography. 
 Electrophoretic Mobility Shift Assay (EMSA) was used to identify specific tRNAiMet  
binders as shown in figure 2.3. Of the 3 Fab clones identified from the YSGRX control library, 
none of them were able to cause a gel shift of tRNAiMet suggesting they were either weak or non-
specific binders. This is not surprising because the control library was not optimized to produce 
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Fabs intended to bind structured RNAs. Of the 3 Fab clones identified from the YSGR Min 
library, Fab 7 produced a distinct gel shift while the other two Fabs did not.  
Filter Binding Assay 
To confirm the ability of Fab 7 to bind to tRNAiMet and determine its binding affinity, the 
filter binding assay was utilized. This method is more sensitive than the gel shift assay and can 
distinguish between strong and weak binders. In this method, 32P labeled RNA is only detected 
on the nitrocellulose membrane when it is bound to the Fab protein and the remaining RNA 
binds to a positively charged nylon membrane. To obtain a binding curve, 10 concentrations of 
Fab were used. A binding curve was generated by plotting the percent RNA bound over the Fab 
concentration. The results as shown in figure 2.4 indicate a binding affinity with a Kd value of 
59 ± 3 nm from the average of 6 experiments.  Indeed, Fab 7 is a high affinity binder of 
tRNAiMet. The remaining Fabs were also subjected to the filter binding assay to determine if they 
could be low affinity binders, however no binding was observed confirming the results of the 
EMSA assay (Data not shown). This suggests that the frequency of selected clones from phage 
ELISA is not a good indicator of binding affinity since Fab 7 was only identified as a single 
clone. 
In vitro Translation Assay 
We hypothesized that a tight tRNAiMet-binding Fab should be able to inhibit the 
translation process. The tRNAs are rather small, only about 25 kD in size. Thus a Fab that is 
roughly 48 kD would be expected to bind to a large surface area of the target antigen, therefore 
likely able to block interactions with native tRNAiMet binding partners and disrupt the translation 
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process. Since Fab 7 was shown to be a tight binding Fab to tRNAiMet, we hypothesize that Fab7 
should be able to inhibit protein synthesis in vitro. As such a human in vitro translation kit was 
utilized containing the translation components necessary (including tRNA, ribosomes, and 
accessory proteins) to produce full length human proteins in vitro. 
 In our experiment, we attempted to inhibit the synthesis of GFP by measuring output 
fluorescence, where inhibition would be observed by a reduction in the fluorescence signal due 
to less GFP production. The assay was performed using a mock PBS control, and multiple 
concentrations of Fab 7 or a control Fab that was not designed to bind to the translation 
machinery. Experiments were performed in triplicates and averaged with background signal 
(PBS) subtracted. Figure 2.5 is a representative plot of two separately repeated experiments. As 
expected, the mock treated control was shown to permit a strong fluorescence signal indicating a 
successful translation reaction. When any concentration of the control Fab was utilized, there 
was no significant difference in fluorescence compared to the mock treated control. However 
when Fab 7 was utilized at concentrations of 10, 20, and 40 µM respectively, fluorescence was 
decreased in a dose dependent manner. The data suggests that Fab 7 can successfully and 
specifically inhibit protein synthesis compared to the control Fab. The data is in agreement with 
the idea that an RNA binding Fab binding tRNAiMet could block the initiation step of translation. 
Conclusions 
Phage display libraries have been optimized and utilized successfully to generate 
monoclonal protein binding Fabs and other proteins of interest.26 However, they have been 
minimally utilized to generate RNA binding Fabs. In part, this was due to the fact that phage 
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display libraries were not optimized to bind to structured RNAs. The YSGR Min library was 
then created to address this issue.19 When we performed phage display on tRNAiMet as a model 
human structured RNA, 4 initial clones were identified from the phage ELISA screen from 
YSGR-min but only 3 clones were identified from the YSGRX library. Ultimately only 1 Fab 
which was identified from the YSGR-min library, Fab 7, was found to successfully bind to its 
target and with high affinity. This data combined with the previous results with other RNA 
targets suggests that YSGR-min is truly a superior library to its protein library counterparts in 
selecting RNA binding Fabs. 
 We hypothesized that due to the size of tRNAiMet being smaller to that of a humanized 
Fab, binding of a Fab to tRNAiMet would likely inhibit its interactions with the translation 
machinery since a large portion of the RNA surface area would be sterically hindered by the Fab. 
As predicted, we were able to show inhibition of translation in vitro in a dose dependent manner 
with Fab 7 where as a control Fab was not. Although the data suggest Fab 7 is inhibiting the 
translation initiation process, more work is needed to evaluate which specific interactions with 
other macromolecules Fab 7 is disrupting. Additionally, inhibition of Fab 7 in vivo is a future 
step towards potentially treating human disease such as cancer, where tRNAiMet was shown to be 
upregulated.  
 We have thus successfully demonstrated the proof-of-concept of developing a Fab that 
binds to a human structured RNA and that this Fab may have a function of clinical significance 




Materials and Methods 
Cloning of RNA templates 
 Vertebrate tRNAiMet DNA gene was generated by recursive PCR from the respective 
DNA oligonucleotide sequences (Integrated DNA Technologies) with an EcoRI restriction site 
and T7 promoter sequence at the 5' end (two 5’ guanisines were also inserted at the transcription 
start site to improve RNA yields in in vitro transcription) and EarI site and HindIII restriction 
sites at the 3' end. The resulting DNA PCR product was cloned into pUC19 plasmids between 
the 5' EcoRI and HindIII 3' restriction sites via published protocols (cite the YSGR min JMB 
paper). Tagged vertebrate tRNAiMet was cloned using the same procedure except that a 29-
nucleotide tag (GCTTTAGGTCGACTCTAGAGGATCCCCGG) was fused to the 3' end.  
In Vitro Transcription of RNAs 
 The tRNAiMet plasmids were amplified in JM109 cells and purified by standard midi prep 
(Qiagen #12143). Plasmids (100 µg) were linearized with 20 units EarI in 1X Buffer 4 (New 
England Biolabs #B7004S) at 37°C overnight. Linearized plasmids were verified by agarose gel 
electrophoresis in 0.5x TBE running buffer (44.5mM Tris base, 44.5mM boric acid, 1mM 
EDTA) and purified via PCA extraction and ethanol precipitation, then dissolved in TE buffer 
(10 mM Tris-HCl pH 8, 1 mM EDTA). RNAs were transcribed in vitro with T7 RNA 
polymerase (45 µg/mL) using 50 µg/mL of linearized template in 40mM Tris pH 7.9, 25 mM 
MgCl2, 2 mM spermidine 3 HCl, 10 mM DTT, 25 mM of all four NTPs, and 0.008 U/µL 
TiPPase in the presence of 0.01 U/µL RNase Inhibitor (5 PRIME) at 37°C overnight. The 
transcribed RNAs were treated with RNase free DNAse I (0.5 Units/µg plasmid) and CaCl2 (1 
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mM) at 37°C for 30 min, then buffer exchanged into 2 mM sodium citrate, pH 6.5 and purified 
on a 6% denaturing polyacrylamide gel electrophoresis (29:1 bis:acrylamide, 7M urea, 0.5x 
TBE) in 0.5x TBE running buffer, excised from the gel under UV illumination, and then 
electroeluted into TE buffer. RNAs (sequence: 
ggAGCAGAGUGGCGCAGCGGAAGCGUGCUGGGCCCAUAACCCAGAGGUCGAUGGA
UCGAAACCAUCCUCUGCUA, lower case g indicates the foreign guanosines added for 
transcription efficiency) were then purified via PCA extraction twice then ethanol precipitation, 
and dissolved in TE buffer. 
A biotin-linked complimentary single stranded DNA sequence was annealed to the 
tagged RNA by combining 2.5 nmoles of tagged RNA with 2.75 nmoles (1.1 eq.) of the 
biotinylated DNA oligomer in 10 mM Tris pH7.5 and 200 mM NaCl, incubating at 90°C for 1 
min followed by 10 min at RT. All RNAs were stored at -20°C. 
Selection for RNA binding Fabs 
 For the first round of selection, 0.5 nmoles of biotinylated tagged tRNAiMet was folded in 
250 µL PTEM (PBS [137 mM NaCl, 3 mM KCl, 8 mM Na2HP04, 1.5 mM KH2PO4 pH 7.2], 
0.05% Tween-20, 2.5 mM EDTA, 12.5 mM MgCl2, and 0.032 U/µL RNAse-Inhibitor and 
incubated at 50°C for 20 min followed by RT for 10 min. Then 2.7 mL of phage library stock 
(~1011-12 cfu/mL) was precipitated in 25 mL PBS and 5.4 mL PEG/NaCl (20% w/v PEG 8000 
and 2.5 M NaCl) by incubating on ice for 5 min and centrifuging at 27 kg. The supernatant was 
discarded and the phage was resuspended in 750 µL Solution A (PBS, 0.67% BSA, 0.067% 
Tween-20, 3.34 mM EDTA pH 8.0, 16.67 mM MgCl2) and transferred into a microcentrifuge 
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tube. Then a final concentration of 0.02 U/ µL SUPERase-In (Ambion #AM2690), 0.16 U/µL 
RNase Inhibitor and 1mg/mL streptavidin (SAV) were added to 750 µL phage solution to a total 
volume of 1 mL. 
To immobilize the RNA, the folded biotinylated RNA was then added to 1 mL pre-
washed SAV coated magnetic beads (Promega Z5482 MagneSphere® Paramagnetic Particles) 
shaking for 15 min at RT. Free biotin was added to the solution (50 µM) and incubated for 10 
min with shaking at RT. The beads were then washed thrice with 500 µL PTEM. Then 1 mL of 
the complete phage solution was added to the immobilized RNA and incubated while shaking for 
15 min at RT. The solution was then washed twice with 1 mL PTEM/gly (PTEM + 5% glycerol) 
supplemented with SUPERase-In (0.04 U/µL) and then resuspended in 0.5 mL of PBS. To 
amplify the selected phage particles, XL1-blue cells from a 1mL overnight starter culture was 
added to 20 mL of 2YT (1.6% Tryptone, 1.0% Yeast extract, and 0.5% NaCl) with tetracycline 
(10 µg/mL) and incubated for 37°C for about an hour (or until an OD600 reaches between 0.6 and 
0.8 for the preparation of the log-phase cells). The re-suspended phage was then added to 5 mL 
of the log-phase XL1-blue cells and incubated at 37°C while shaking for 20 min. Then M13K07 
helper phage (1010 pfu/mL) was added and continued shaking at 37°C for 45 min. The culture 
was then transferred to 20 mL 2YT containing ampicillin (100 µg/mL) and kanamycin (25 
µg/mL) and incubated at 37°C for 19 hours. 
The phage solution (30 mL overnight culture) was then repurified by centrifugation at 
17.5 kg for 10 min at 4°C and repeated 1 or more time to remove cellular debris. The phage 
particles were then precipitated by incubating with 1/5 culture volume of PEG/NaCl for 5 min at 
4°C and then pelleted by centrifugation at 27 kg for 10 min. The supernatant was discarded and 
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the phage pellet was re-dissolved in 10 mL of ice-cold PBS and centrifuged 27 kg for 5 min at 
4°C to remove insoluble debris. The supernatant was then re-precipitated, centrifuged, and re-
dissolved in 400 µL ice-cold PBS. Purified phage particles were stored at -20°C in 50% glycerol. 
For round 2 of selection and subsequent rounds, 10 pmoles of biotinylated tagged tRNAiMet was 
folded in 11 µL PTEM and incubated at 50°C for 20 min followed by RT for 10 min. Then 80 
µL phage glycerol stock was precipitated in 720 µL PBS and 160 µL PEG/NaCl, then incubated 
for 5 min at 4°C. The precipitated phage was then pelleted at 23.7 kg and reconstituted in 100 µL 
Solution B (PBS, 0.05% Tween-20, 2.66 µM EDTA pH 8, 13.26 mM MgCl2 and 0.57% BSA), 
added to 60 µL of pre-washed SAV magnetic beads and was incubated at RT shaking for 30 min. 
The supernatant was then collected and the beads were washed with 90 µL Solution B and 
combined with the supernatant for quantitative transfer. 
The following steps were then performed using a KingFisher Magnetic Particle Processor 
(VWR # 14230-360), microplate of 8-well (wells A-H) strips (VWR # 14230-404), 
corresponding magnetic tip combs (14230-402) and was custom programmed accordingly 
(RNA_2nd) with each column representing a different RNA or the control running in parallel: 
88.5 µL phage in Solution B, 5 µL 4 U/µL RNase Inhibitor, 0.5 µL of 10 µg/µL sheared salmon 
sperm DNA, and 6 µL pre-folded biotinylated RNA in PTEM were loaded in row A with 6 µL 
PTEM substituted for the folded RNA in the control column and incubated mixing for 15 min. 
Then 30 µL of pre-washed beads in row B were transferred to well A, mixing for 15 minutes. 
Then the beads were transferred from well A to well C and were washed for 5 minutes in 100 µL 
PTEM/gly and 1 µL of 0.5 mM free biotin. To remove unbound phage particles, the beads were 
transferred to wells D-G in tandem, and washed for 30 sec in each well in 100 µL PTEM/gly. 
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The retained phage particles were then eluted from the beads for 2 min in well H containing 50 
µL PBS, 3.13 µL 80% glycerol, and 1 µL 110 ng/µL biotinylated RNase A and the beads were 
discarded in well F. 
To further purify the eluted phage particles and remove bead binders, postelution_capture 
program was executed on the KingFisher. Well H from the RNA_2nd program was manually 
transferred to well A of a new set of microplate strips. In well B, 20 µL of unwashed beads with 
30 µL PBS wash transferred to well C to be washed in 50 µL for 20 sec. The washed beads were 
then transferred to well A, and incubated for 10 min. The beads were then removed from well A 
and disposed of in well C. The comb was then washed in well D containing 100 µL PBS for 20 
sec. In well D, 20 µL of unwashed beads with 30 µL PBS wash transferred to well E to be 
washed in 50 µL for 20 sec. The washed beads from well E were then transferred to well A, and 
incubated for 10 min. The beads were then discarded in well F. 
The selected phage particles in well A were used for phage titering (3 µL) and for 
amplifying (remaining phage particles) for the next round of selection. For amplification, the 
phage eluate was added to 1mL of log phage XL1 blue cells in 2YT containing tetracycline (10 
µg/mL) incubating shaking at 37°C for 20 min. Then M13K07 helper phage (1010/mL) was 
added and incubated while shaking at 37°C for 45 min. The entire culture contents were 
transferred to 30mL of 2YT containing ampicillin (100 µg/mL) and kanamycin (25 µg/mL) and 
incubated while shaking at 37°C for 19 hours. 
Phage titering was performed by infecting 45 µL log phase (OD600 between 0.6 and 0.8) 
XL1-blue cells grown in 2YT (tetracycline 10 µg/mL) with 10 µL serial dilutions of input and 
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output phage including the control from 10-5 to 10-9 and incubating for 15 min at RT. Then 40 µL 
of each infected serial dilution was spread on an LB/Amp plate divided in a radial pattern, dried 
and incubated at 37°C overnight. Colonies were then counted for each dilution and reduction 
ratio and enrichment were calculated. Reduction ratio is defined as input cfu / output cfu. 
Enrichment is defined as output cfu / control cfu. 
For selection using stringent conditions after round 2 or later, the RNA was pre-diluted 
10 fold in PTEM to maintain the same reaction volume and the competitor, sheared salmon 
sperm DNA was increased 10 fold to 0.5 µL of 100 µg/µL stock solution. 
Phage ELISA & Sequencing 
Phage dilution buffer was prepared which contains 1050 µL 10x PBS,52.5 µL 10% 
Tween20, 52.5 µL 500 mM EDTA, 131 µL 1M MgCl2,52.5 mg BSA,105 µL 10 mg/mL sheared 
salmon DNA, 175 µL 40 mg/mL heparin, 52.5 µL 200 mM Vanadyl ribocomplex, and 3 µL 
4U/µL RNase IN in a total volume of 7ml without filteration. Anti-M13 antibody/HRP conjugate 
solution was prepared by adding the following components to 10 mL PTEM: 50 mg BSA and 50 
µL 200 mM Vanadyl ribocomplex. The Vanadyl ribocomplex was allowed to dissolve, then 2 µL 
Anti-M13 antibody/HRP conjugate was added to the mixture. Both phage dilution buffer and 
Anti-M13 antibody/HRP conjugate solution were made fresh for each experiment. 
A Maxisorp plate pre-coated with neutravidin was blocked for 1 hour while shaking at 
RT by 200 µL per well of blocking buffer (1% w/v BSA in PTEM) and covered with adhesive 
film. Biotinylated tRNA was folded by incubating 1.25 µM in PTEM (100 µL total) at 50°C for 
20 min followed by an additional 10 min at room temperature. The folded RNA was then diluted 
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50 fold in PTEM (5mL total). After the 1 hour incubation, the Maxisorp plate was washed 4 
times with Rinse Buffer A (PBS + 0.05% Tween-20). The RNA was then added to the plate in 
the odd numbered columns at 100 µL per well (25 nM) and PTEM was added to the even 
numbered columns at 100 µL per well. The plate was then covered with adhesive film and 
incubated for 30 min while shaking at RT. After the 30 minute incubation, the Maxisorp plate 
was washed 6 times with Rinse Buffer B (PTEM). Phage was diluted in Phage Dilution Buffer 
and then 100 µL per well was transferred to the Maxisorp plate (1 colony per phage and control).  
The Maxisorp plate was then incubated for 30 min at RT shaking and covered with 
adhesive film.  The Maxisorp plate was then washed 6 times with Rinse Buffer B. The Anti-M13 
antibody/HRP conjugate solution (100 µL per well) was incubated at RT for 30 min while 
shaking at RT. The Maxisorp plate was then washed 6 times with Rinse Buffer B and then 
washed twice with Rinse Buffer C (PBS, 2.5 mM EDTA, 12.5 mM MgCl2). The TMB substrate 
(100 µL per well) was added for 5-10 min covered to protect from light and then quenched with 
1M phosphoric acid (100 µL per well). The absorbance was then read at λ450 on a plate reader 
using water as the blank. 
Corresponding positive colonies were inoculated in 5mL 2YT with ampicillin (100 
ug/mL) and incubated overnight while shaking at 37°C. Plasmids of each clone were isolated and 
purified by Miniprep (Qiagen QIAprep Spin Miniprep Kit #27107) and then sent for sequencing. 
Isolation of Single Stranded DNA 
Fab phagemids were transformed into CJ236 cells via electroporation. Cells were then 
inoculated in 1 mL 2YT containing Ampicillin (100 ug/mL) and Chloramphenicol (10 ug/mL) 
30 
 
and incubated at 37°C shaking for about 6 hours until slightly cloudy.  Log phage cells were 
infected with M13KO7 helper phage (1010 pfu/mL) shaking for 10 min at 37°C then 300 µL 
were transferred into 30 mL 2YT containing  ampicillin (100 ug/mL) and uridine (0.25 µg/mL) 
and was incubated at while shaking at 37°C for 19 hours. The culture was centrifuged for 10 min 
at 27 kg at 4°C and supernatant containing the phage was collected and precipitated with 20% 
w/v PEG, 2.5 M NaCl. Phage was pelleted by centrifuging for 10 min at 24 kg at 4°C, 
supernatant removed, and then resuspended in 0.5 mL PBS. Single stranded DNA was then 
isolated from the phage according to the manufacturer’s instructions using the Qiagen Qiaprep 
Spin M13 kit #20004. 
Kunkel Mutagenesis to Produce Soluble Fabs 
 The Kunkel primer 
(TCTTGTGACAAAACTCACACATAGGGCCGGCCCTCTGGTTCC) was 5’ phosphorylated 
by incubating a mixture of 660 ng primer, 1 mM ATP, 5 mM DTT, 10 units T4 PolyNucleotide 
kinase in 1X TM buffer (0.5 M Tris pH 7.5, 0.1 M MgCl2) at 37°C for 1 hour. The 
phosphorylated primer (66 ng) was then annealed to the single stranded DNA Kunkel template (1 
µg) in 1X TM buffer by incubating at for 90°C for 1 minute followed by 50°C for 3 min The 
template was then filled in using a mixture of 0.4 mM ATP, 1 mM DTT, 6 mM DTT and 240 
units T4 DNA ligase then spun down. Then 3 units of T7 DNA polymerase was added and 
incubated at 37°C for 1.5 hours. The Kunkel product was then PCA extracted twice, ethanol 
precipitated, and dried by high vacuum. The pellet was then re-dissolved in 5 µL Sterile water 
and 1 µL was used for electroporation into 34B8 cells (40 µL of electrocompetent cells  per rxn) 
using 1.4 kV. Electroporated cells were placed in 960 mL of SOC media (100 µL total volume) 
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and then incubated while shaking at 37°C for an hour. 100 µL was spread onto an LB/AMP plate 
and incubated overnight at 37°C. Colony PCR was used to evaluate the successful incorporation 
of Kunkel stop codons. Single colonies were added to a solution of Taq buffer, 2.5mM dNTPs, 
0.05 Units/µL Taq Polymerase, and 2.5 ng/ µL of both the forward (FabHCupF) and reverse 
(FabStopR) primers and the colony PCR program was executed. PCR Products were evaluated 
on agarose gel electrophoresis (1% gel 45 min 100V) and stained with ethidium bromide. 
Expression of Soluble Fabs 
Plasmids (phagemids) containing Fab sequences were transformed into 34B8 cells via 
electroporation and verified by colony PCR. 34B8 cells were grown in 30 mL starter flasks for 
16 hours in 2YT supplemented with ampicillin (100 µg/mL) at 30°C while shaking, and then 5 
mL of log phase cells were transferred into CRAP media for 24 hours at 30°C while shaking. 
CRAP media was prepared fresh each time by dissolving 1.785 g (NH4)2SO4, 0.355 g 
NaCitrate•2H2O, 0.535 g KCl, 2.68 g yeast extract, and 2.68 g HyCase SF Casein in a total 
volume of 0.5 mL, titrated to a pH of 7.3 then autoclaved in a 2.8 L baffled flask. After cooling, 
the media was completed by adding 55 mL 1 M MOPS pH 7.3, 5.5 mL 50% w/v glucose, 3.5 mL 
1M MgSO4, and 0.5 mL 100 mg/mL ampicillin. Fabs were purified on Protein A sepharose 
Columns (Amersham) and Fab 7 was further purified on high salt cation exchange columns for 
the in vitro translation assay. SDS-PAGE electrophoresis was used to verify Fab proteins. 
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Gel Shift Assay 
tRNAiMet (20 pmoles) was folded in 6.5 mM Tris pH 7.5, 25mM MgCl2 and 150 mM 
NaCl by incubating at 50°C for 20 min and 10 min at RT. Then a 1.5 molar ratio of expressed 
Fabs or mock (Tris pH 7.5) was incubated at RT for a half hour. The folded RNA was 
electrophoresed on a 8% native polyacrylamide gel (29:1 bis:acrylamide, 5 mM MgCl2, 89mM 
Tris base, 89mM Boric acid) in 0.5x TBE running bufferfor 70 min at 120 volts. Gels were 
stained with StainsAllTM for 10 min and destained with a high intensity light source before 
imaging. 
Filter Binding Assay 
2 µL32P labeled tRNAiMet (between 140 and 650 kpcm) was diluted in 4546 µL binding 
buffer (1x PBS, 0.1 mM EDTA, 10 mM MgCl2) and folded by incubating for 10 min at 50°C 
followed by an additional 10 min at RT. To the folded RNA, 130 μL 40 mg/mL heparin was 
added as a competitor and 2 µL RNase inhibitor was added to inhibit RNA degradation. Serial 
dilutions of Fabs were made starting at 20 µM and diluted to as low as 39 nM in 1x PBS. 36 µl 
folded cognate tRNAiMet was added to 4 µl of diluted Fabs for each concentration and incubated 
shaking for 30 min at RT. Both the Nylon and nitrocellulose membranes were equilibrated in 
binding buffer for at least 15 min prior to use and assembled in the filter binding apparatus with 
the nitrocellulose membrane on top. Fab-RNA mixtures were applied to the filter binding 
apparatus under high vacuum with 100 µL cold binding buffer added just before and after the 
addition of the mixture under high vacuum. After all samples were run, an extra 5 min of 
vacuum was applied, then membranes were air dried for 15 min, exposed to a PhosphorImager 
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screen, scanned by  Phosphoimager SI (Molecular Dynamics), and quantified by ImageQuant 
(Molecular Dynamics). Binding affinities were calculated by fitting the data to the equation: 
fraction bound = M × [Fab]n/(Kd 
n + [Fab]n), where Kd is the binding constant, M is the maximum 
fraction of RNA bound at the highest Fab concentration, and n is the Hill coefficient. Each 
binding assay was carried out at least in duplicates. 
In Vitro Translation Assay 
The 1-Step Human Coupled IVT Kit - DNA (Thermo Scientific #88882) was purchased 
and the GFP control plasmid was transformed into JM 109 cells, amplified, and purified using a 
midi prep kit (Qiagen #12143), as the original translation kit was not intended for our purposes. 
For each reaction, 12.5 µL of HeLa cell lysate was pre-incubated with Fab 7, control Fab, or 
mock PBS for 30 min at RT. Then the kit reagents were added in the following order: 2.5 µL of 
accessory proteins, 5 µL of reaction mix, and GFP DNA (0.5 µg/µL stock) and then placed on 
ice. Total volume for each reaction was not to exceed 25 µL. The samples were mixed by 
tapping and spun down at 21.1 kg for 1 minute to remove insoluble material. The supernatant of 
each reaction was transferred to a 96 well flat-bottom black plate, and the samples were spread 
evenly and any bubbles removed by centrifugation for 2 min at 2.85 kg at 4°C. Plates were then 
covered to protect from light and incubated for half an hour on ice. Fluorescence was measured 
on a plate reader (Tecan Infinite M200PRO), with 475/512 excitation and emission filters at 
30°C at indicated time points shaking just before each read. The plate was covered in PCR 
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Figure 2.1. A Filamentous phage. The pVIII protein is expressed in thousands of copies to form 
a filament encapsulating the single stranded circular genome of the phage and its length depends 
on the size of the packaged DNA. In phage display, the Fab is fused to the pIII surface protein. 






Figure 2.2. Schematic of the selection process. RNA antigen binders remain attached to the bead 
while non-binders are washed away. Bound phage particles are eluted, amplified, and the cycle 





Figure 2.3. Gel shift assay demonstrating that Fab 7 from the YSGR Min library is able to bind 













































Figure 2.4. Binding curve for Fab 7 as a result of the filter binding assay. Data points are the 
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Figure 2.5. Result of the in vitro translation assay measuring GFP fluorescence counts as a 
function of time. Fab 7 was able to inhibit the production of GFP in a dose dependent manner. 
The control Fab did not show any significant decrease in fluorescence compared to the mock 
treated control. Ex / Em 475 / 512. 
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2 1.36 x 107 2.95 
3 2.51 x 106 28.75 
4 5.66 x 105 2,380.95 
3 (stringent) 1.47 x 107 17.39 
4 (stringent) 1.23 x 105 47.05 
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2 3.43 x 105 0.35 
3 2.66 x 105 0.57 
4 6.78 x 105 442.95 
4 (repeated) 6.69 x 105 230.63 
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Table 2.3. Sequencing results of unique Fab clones identified by phage ELISA screening 
Library Clone Frequency L1 L2 L3 H1 H2 H3 
YSGRX 1 18/24 SVSS SASS SSYSSS SISSSI YIYPSSGSTY YRYRSGHAL 
YSGRX 2 4/24 SVSS SASS HYTTPP SISSSI YIYPYSGSTY RSYRYYYGYYGF 
YSGRX 3 2/24 SVSS SASS HYTTPP YISSYSI YIYPSSGSTS RSYRYYYGYYGF 
YSGR Min 4 11/21 GSGYS YGAYSLSGGVPSR SSYGLV NISRSGI RSRPYRGSTG GSRSRSGGL 
YSGR Min 5 1/21 SSSSS SSASRLSSGVPSR SYRYPI NISRSG SYRSYRGSTS YGYRSRYGGF 
YSGR Min 6 8/21 GSGYG YSASRLSGGVPYR SGYGLV NISRSG RSRPYRGSTR GSRSRYSGL 
YSGR Min 7 1/21 SSRYR YGAYRLSSGVPYR GSSYPV NFSRSGI GSGSSRGYTR SGSGSRYAL 
Note that only the variable CDR regions are shown for simplicity. L = light chain, H = heavy chain 
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CHAPTER 3: CHARACTERIZATION AND SPECIFICTY OF A FAB 
THAT BINDS HUMAN INITIATOR TRNA 
Introduction 
 Antibodies are naturally occurring components of the vertebrate immune system. Their 
high-affinity and high-specificity allows them to bind target antigens such as toxins, virus 
particles, bacteria and their components, and parasites without targeting the host organism.1 This 
provides a means for selective destruction of the invasive foreign antigens while leaving the cells 
of the host organism unharmed. Owing to the development in monoclonal antibody technology 
in preparation, derivatization and characterization, antibodies have been heavily utilized as 
molecular biology tools as well as diagnostics and therapeutics for numerous diseases.1-5 For 
example, the therapeutic antibody Trastuzumab is selective for the Her-2 receptor found 
upregulated primarily on breast and select other cancers.6 Patients diagnosed with Her-2 positive 
breast cancers previously had poor prognosis. Trastuzumab and Trastuzumab-conjugated 
chemotherapeutic drugs can target the tumor directly to selectively kill tumor cells.6,7 Previously 
the chemotherapeutic drug was administered to the patient systemically where it could come in 
contact with normal cells and thus side defects were harsh and efficacy was reduced due to the 
lack of targeting.8,9 
 Antibodies come in various isotypes, IgG, IgA, IgM, IgD, and IgE.1 It is the human 
soluble IgG molecules secreted by mature plasma cells (or recombinant) that are utilized as 
therapeutics.4 An IgG molecule contains two identical light chains and two identical heavy 
chains. Both heavy and light chains contain variable regions while only the heavy chain contains 
a constant region called the Fc portion.1 While the constant region remains the same for all 
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humans, the variable regions (Fabs) differ from person to person. Within these variable regions 
are the hypervariable regions known as the complementary determining regions (CDRs) which 
are the specific portion that binds to the antigen.1 When designing antibodies to be used as 
therapeutics in humans, it is important to use human or humanized antibodies as therapeutics so 
that an immune response is not mounted against the foreign antibody itself.10 
 When the immune system of an animal produces antibodies, it produces polyclonal 
antibodies which are a collection of antibodies that can bind to a single antigen, but may bind to 
different portions of the same antigen called epitopes.1 These antibodies may have different 
binding affinities and expressed in different quantities. While useful as molecular biology tools, 
polyclonal antibodies are not pure and therefore are not used as therapeutics. Instead monoclonal 
antibodies (Mabs) are identical clones of a single antibody.4 Monoclonal antibodies can be 
produced in several ways. One is to isolate plasma cells that secrete an antibody of interest and 
then fuse it with a cultured cancerous plasma cell, a myeloma cell.1 The resulting hybrids will 
continue to grow and secrete only a single antibody.1 
 In phage display technology, a recombinant human IgG molecule or individual Fab is 
cloned into a phagemid vector as described in the previous chapter.11,12 The introduced genes are 
condensed and lack introns so that they can be correctly expressed by the prokaryotic expression 
machinery and can be re-packaged into phage particles as needed. Using bacteria specifically 
engineered to assemble correctly structured Fabs that are secreted into the periplasm, fully 
functional humanized Fabs can be secreted and isolated from the bacteria.11,13 
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 Although antibodies are raised against and are specific for binding to a certain antigen, 
there is usually some degree of cross-reactivity.14 Many commercially available antibodies will 
bind to the target antigen but also can identify other proteins when performing western blotting 
analysis or affinity chromatography.3 Affinity maturation is one method that can enhance 
binding to the target antigen while minimizing cross-reactivity with other proteins.15 
 We previously described the production of an antibody Fab that binds to in vitro 
transcribed human initiator tRNA (tRNAiMet). Although several antibodies have been generated 
that bind to structured RNAs, specificities of these Fabs were not fully characterized.16-18 
Characterization of the specificities of the Fabs and their cross-reactivities towards cellular 
RNAs are extremely important if the RNA targeting Fabs are to be used in diagnostic or 
therapeutic applications. 
 Furthermore, the previous selection of Fab 7 was raised against in vitro transcribed RNA. 
In vitro transcribed tRNAs are highly representative of their native structures and can 
spontaneously fold in the presence of magnesium to the correct conformation.19 In addition, 
unmodified tRNAs have been shown to retain the correct binding ability and functionality with 
their cognate synthetases, elongation factor Tu (EF-Tu), and the posttranscriptional modification 
enzymes.19-22 However, in vitro transcribed tRNAs are slightly different than their native 
counterparts in that the native mature tRNAs contain base modification as shown in figure 3.1. 
The tRNAiMet contains an additional 8 base modifications not present in the in vitro transcribed 
tRNAs.23 Also the in vitro transcribed RNAs have two additional guanosine residues at the 5' end 
which enhance in vitro transcription.24 Many of these modifications are needed to exclude 
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tRNAiMet from being utilized as an elongator tRNA as it was shown that removing the 
modifications did not interfere with its ability to behave as an initiator.25-30 
 We hereby describe the characterization of the specificity of Fab 7 by checking the cross 
reactivity of this Fab toward several non-cognate RNAs using both filter binding assays and 
Elecrophoretic Mobility Shift Assay (EMSA) and then Surface Plasmon Resonance (SPR) to 
determine additional kinetic parameters. We further investigated the ability of Fab 7 to disrupt 
protein synthesis by evaluating its ability to inhibit the charging of tRNAiMet with methionine by 
Methionyl tRNA Synthetase (MARS). We then developed a novel blotting method (dubbed the 
Northwestern Blot) to inspect the cross-reactivity of Fab 7 in total cellular RNA; a technique that 
would be applicable to all RNA binding Fabs. Northern blotting was used to confirm tRNAiMet 
location. 
Results and Discussion 
Further Characterization of Fab 7 Binding and Specificity Using Purified Biological Samples 
Investigation of the Cross-Reactivity of Fab7 Using EMSA 
 The elongator tRNAs are thought to have the same basic tertiary "L" shaped structure 
which differs slightly from the initiator tRNA based on molecular modeling.31,32 Indeed, yeast 
initiator tRNA is thought to be more similar in structure to human initiator tRNA than human 
initiator tRNA is to the human elongator tRNAs.27,33,34 As such, tRNAeMet was selected to 
represent the elongator tRNAs and was in vitro transcribed and analyzed to see if Fab 7 could 
distinguish between human initiator and elongator tRNAs. When folded and run on an RNA 
native gel, both tRNAs were shown to migrate at the same position as expected. 
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 EMSA was then used to identify if Fab 7 could bind to tRNAeMet, a random unrelated 
structured RNA P4-P6, and commercial E. coli total tRNA where a gel shift would indicate 
positive binding. As demonstrated in figure 3.2, Fab 7 was only able to cause a distinct gel shift 
for tRNAiMet , but not the other RNAs. Some streaking was observed when Fab 7 was added to 
P4-P6 RNA, however, when adding Heparin to the samples as a negatively charged competitor 
prior to re-running the gel, the streaking disappeared completely indicating that streaking in the 
first gel was due to non-specific binding (data not shown). Furthermore, tRNAiMet was still gel 
shifted by Fab 7 in the presence of Heparin. 
Investigation of the Cross-Reactivity of Fab7 using the Filter Binding Assay 
 EMSA is a qualitative assay that can be used for rapid identification of tight binding 
interactions. However, the technique is not quantitative and is not sensitive enough to detect 
weak non-covalent binding interactions. To further verify the results of EMSA, the filter binding 
assay35 was performed using 32P radiolabeled tRNAiMet, tRNAeMet and a random unrelated RNA, 
VCII66. As expected, the nitrocellulose membrane showed a signal at most of the Fab 7 
concentrations used when tRNAiMet was the RNA and yielded a binding affinity similar to the 
one obtained previously. None of the other RNAs could be detected on the nitrocellulose 
membrane above the background signal indicating that Fab 7 was not able to bind to these 
RNAs. 
Determining the KD and koff Value of Fab 7 Using SPR. 
SPR is an even more sensitive technique than the filter binding assay for determining the 
binding affinity of a binding pair and does not require the use of radiation.36 The technique does 
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require for one of the binding partners to be immobilized, which for proteins can easily be 
achieved using EDC chemistry. In our case, however, we immobilized a biotinylated version of 
Fab 7 to a neutravidin coated chip where the biotin is attached at a site far from the CDRs so 
antigen binding would be guaranteed to not be disrupted. (The synthesis of the biotinylated Fab 
is described later in Chapter 4 of this dissertation.) The tRNAiMet was then injected and flowed 
over the immobilized Fab at various concentrations where binding was observed in real time and 
dissociation was also observed in real time as the RNA was removed. Using the Tracedrawer 
software, a bivalent binding model yielded two KD values. 
The first KD value was determined to be 34.6 ± 0.092 nM, in agreement with the filter 
binding affinity data as shown in figure 3.3. Additionally, because SPR also evaluates the 
removal of the binding molecule in real time, a koff value can also be obtained which was 
determined to be 9.57 e-03 ± 2.40e-5 (1/s). This low value demonstrates that tRNAiMet 
dissociates very slowly from Fab 7. The second KD value was determined to be 1.87 ± 0.31 M 
with a koff value of 0.213 ± 0.001 (1/s). This high molar range binding affinity combined with a 
fast dissociation suggests the detection of non-specific binding. Since tRNAiMet like RNAs in 
general have high negative charge due to their phosphate backbones, it is not surprising that Fab 
7 with a theoretical pI of 9.05 is able to weakly bind tRNAiMet non-specifically via electrostatic 
interactions. This may also explain why Fab 7 was able to cause streaking of the unrelated RNA 
fragment P4-P6 in the gel shift assay however the filter binding assay was not able to detect 
weak binding of the unrelated RNA fragment VCII66. Indeed, the high sensitivity of the SPR 




Biological Activity of Fab 7 in a Clearly Defined System 
Aminoacylation Assay 
We have previously demonstrated that Fab 7 can interfere with in vitro translation 
activity, presumably by binding to initiator tRNA and inhibiting the formation of the pre-
initiation complex which is needed to begin protein translation. However this in vitro system 
uses a proprietary set of reagents which is not fully characterized and well defined. After initiator 
tRNA is first transcribed, it is processed into mature tRNAiMet and then charged with methionine 
by MARS.37-39 The charged tRNAiMet is then ready to bind to the gamma subunit of the 
heterotrimeric protein, initiation factor 2 (EIF2) in the presence of GTP which then begins the 
assembly of the pre-initiaton complex.40,41  
Since Fab 7 was able to inhibit at least one of the steps of in vitro translation, we wanted 
to evaluate the ability of Fab 7 to specifically disrupt tRNAiMet interactions. One method that we 
considered is to evaluate the ability of Fab 7 to inhibit the binding of tRNAiMet to the gamma 
subunit of EIF2 using SPR which is a complex setup that has been planned as a future 
experiment. Currently, however, we wanted to determine if Fab 7 could inhibit the binding of 
tRNAiMet to its cognate synthetase MARS and prevent aminoacylation from occuring. We chose 
to use the inorganic pyrophosphatase coupled malachite green assay as described previously. 
This assay is simple and does not require the use of a radiolabel as with other synthetase kinetic 
assays. When the amino acid methionine and ATP bind to MARs, inorganic pyrophosphate is 
released.42,43 Then tRNAiMet binds to MARs and is charged with the methionine and AMP is 
released. The charged tRNA is then released from the enzyme permitting MARS to bind another 
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ATP, methionine and the tRNA again starting the next cycle.43 Thus inorganic pyrophosphate is 
only released after each subsequent round of catalytic turnover which can be indirectly measured 
by converting pyrophosphate into free inorganic phosphate that can be detected with malachite 
green as an absorbance shift.42 
The tRNAiMet that was first synthesized in our lab was originally made as the human 
encoded gene sequence for determining the binding kinetics or with a tag at the 3’ end for 
immobilizing the RNA during selection, neither of which can be aminoacylated. As shown in 
figure 3.4, MARs detects both the anticodon and the 3’ CCA post-transcriptional 
modification.27,40 Thus in order to perform this assay, we synthesized tRNAiMet-CCA.27 While E. 
coli version of the MARS enzyme (MetRS) is known to be able to bind to eukaryotic tRNAiMet, 
the ability to perform catalysis and charge eukaryotic tRNAiMet as demonstrated with yeast is not 
optimal and therefore the human enzyme was chosen.42,44 Recombinant human MARS isolated 
from HEK 293 cells was purchased from Origene (#TP302932). 
Additionally, before performing the experiment, each of the assay components was 
reacted with malachite green in order to detect any background noise from free phosphate. Only 
the ATP was found to have a low signal not surprising and likely due to mild degradation. 
However, none of the other reagents contained free phosphates above the ddH2O signal. 
Additionally, we had also buffer exchanged Fab 7 and the control protein, 4D5, into a Tris buffer 
because PBS is unsuitable for this assay because it contains free phosphate. Additionally we 
found that HEPES buffer produces high background noise and thus was avoided. 
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After optimizing the reagents to function and reduce background noise, we then 
incubated tRNAiMet in the presence of Fab 7, 4D5 control Fab, or mock ddH2O and then added it 
to a mixture containing L-methionine, ATP, MARS and inorganic pyrophosphatase incubating at 
37°C for an hour and then at RT overnight. Malachite green was then added to measure free 
phosphate by reading the absorbance at λ620nm on a plate reader. Indeed, as shown in figure 3.5, 
Fab 7 is capable of inhibiting the aminoacylation reaction in vitro while the control Fab showed 
only a modest effect. As such, our in vitro transcribed RNA is able to be aminoacylated by its 
enzyme in vitro, suggesting that it is correctly folded and that Fab 7 is able to inhibit this 
interaction. The signal in the negative control was due the small amount of phosphate from the 
ATP. 
Determining the Ability of Fab 7 to Cross-React with Other RNA Species 
Development of the Northwestern Blot 
 The previous sections described the functionality of Fab 7 to inhibit aminoacylation and 
the binding specificity of Fab 7 by challenging it against highly purified RNA species. Indeed, 
Fab 7 did not demonstrate binding toward P4-P6, VCII66, elongator tRNA and an E. coli tRNA 
mix, demonstrating great specificity. However, in order to facilitate its future application in 
targeting tRNAiMet inside live cells, a more rigorous cross-reactivity check against intracellular 
RNAs is needed. In addition, since the selection target was in vitro transcribed which does not 
contain the post-transcriptional modifications, we would like to verify binding of Fab 7 to bona 
fide tRNAiMet. One of the typical assays for verifying the specificity of an antibody toward 
intracellular proteins is to use a western blot. A western blot is capable of checking an antibody’s 
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cross-reactivity to total protein cell lysate.3 Analogous to this, we have designed an RNA 
immunoblotting technique combining the technique of a western blot with the use of Northern 
blot reagents and hence the “Northwestern Blot” for checking specificity of RNA-binding 
antibody against total cellular RNA.  
Northwestern Blot with Protein A-Horseradish Peroxidase (HRP) as a Secondary Antibody 
 In the first attempt at carrying out the northwestern blot, a native RNA gel was utilized 
instead of an SDS-polyacrylamide gel as performed in the EMSA method with folded RNAs. 
However a nitrocellulose membrane is not suitable to transfer RNA without additional UV or 
chemical cross-linking steps which could disrupt the antigen binding site on the RNA. Instead, a 
positively charged nylon membrane (Hybond N+) was utilized which was successfully used in 
the filter binding assay to capture all RNAs. Transfer times were calculated based on the 
manufacturer's instructions of the transfer apparatus which was 16 hours at a constant 25V. The 
membrane was then incubated with 2% (w/v) nuclease free BSA in PTEM binding buffer for 3 
hours at 4°C to ensure proper RNA folding while blocking the membrane. All washing steps 
were performed using PTEM buffer and repeated at least 4 times with ≥ 5 minutes per wash. 
Based on the previously determined binding affinity of Fab 7, we chose a concentration roughly 
double its KD value and utilized Fab 7 at a concentration of 100nM in blocking buffer for 3 
hours. Protein-A HRP was selected as a substitute for secondary antibody due to its known 
affinity for Fabs and protein-A sepharose affinity columns were utilized to purify the Fabs 
initially therefore we rationalized that this was feasible. 
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 After incubation of the membrane with protein-A HRP conjugate at 1:1000 for 3 hours in 
blocking buffer and washing steps, the luminescent substrate was added according to the 
manufacturer’s instructions. The membrane was exposed to x-ray film and then imaged. The gel 
was run in a pattern of "e i e i i" (e and i stand for elongator and initiator respectively) and both a 
native gel stained with Stains-All™ was used to compare to the blot to verify that all 5 RNA 
bands were present. As shown in figure 3.6, the imaged film showed an inverse image only 
selecting for tRNAiMet. The data suggested that there was too much secondary protein-A HRP 
and/or that the membrane was not sufficiently blocked. This was not surprising as the Hybond 
N+ membrane is positively charged and protein A was found to be highly negatively charged 
thus permitting non-specific electrostatic interactions between protein-A HRP and the 
membrane. Since more protein-A HRP was likely bound specifically to tRNAiMet than the 
membrane nonspecifically, rapid consumption of the light emitting substrate by protein-A HRP 
at the tRNAiMet location was likely the cause of the negative image bands observed. 
 In order to reduce the severe background signal several conditions were tried. Blocking 
was increased to 5% BSA in PTEM, Fab 7 as the primary antibody was tried at the same 100 nM 
concentration and also cut in half to 50 nM retaining the same incubation times. The protein A-
HRP was tried at dilutions of 1:10,000, 1:20,000, 1:50,000 and 1:100,000 with the incubation 
times reduced to 2 hours at 4°C. Even at the 1:100,000 concentration, the membrane completely 
lit up after the luminescent substrate was added (a dilution of 1:50,000 or higher was unlikely to 
be sufficient and at 1:20,000 negative bands were not observed). To verify that the protein A-
HRP was the issue, strips of Hybond N+ membrane were equilibrated and blocked overnight in 
5% BSA,  100 µg/mL salmon sperm DNA,  salmon sperm DNA 200 µg/mL,  5% BSA + 100 
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µg/mL salmon sperm DNA,  5% BSA + 200 µg/mL salmon sperm DNA, and  10mg/mL salmon 
sperm DNA, respectively. Then protein A-HRP was added at 1:10,000 (manufacturer-
recommended concentration) for 2 hours shaking and washed 4 times with PTEM for 5 minutes 
each wash before adding the TMB substrate, however, all of the membranes turned blue 
instantly, except for the PTEM only control lacking the protein-A HRP which showed non-
significant color change (a faint signal was detected likely due to air oxidation), indicating that 
there is not a suitable or at least a convenient way to block protein A-HRP from binding to the 
Hybond N+ membrane making it an unsuitable choice for a secondary probe. 
 The non-specific binding of protein A to the hybond N+ membrane may be explained by 
the isoelectric point of protein A which is calculated to be between 4.7 and 5.16 due to the high 
frequency of aspartate and glutamate residues which were the most abundant amino acids found 
in the protein, therefore the overall protein A molecule is heavily negatively charged. Since the 
Hybond N+ membrane is highly positively charged and designed to bind to highly negatively 
charged nucleic acids, it is likely that protein A is strongly binding the membrane through 
electrostatic interactions and is therefore not suitable for our application. Fab 7 on the other hand 
is highly positively charged and has an isoelectric point of 9.05 and therefore should not have 
any affinity to the Hybond N+ membrane. Instead of continuing with protein A-HRP, we 




Northwestern Blot with Anti-Human Fab-HRP as a Secondary Antibody 
 An antibody conjugated with HRP that has known affinity to Fabs was purchased 
(Thermo #31482) and prepared according to the manufacturer’s instructions. Hybond N+ test 
strips were incubated with shaking in 10mg/mL of salmon sperm DNA, 5% BSA, or PTEM 
buffer overnight and then incubated with Anti-Fab-HRP for 2 hours at dilutions of 1:10,000, 
1:20,000, 1:50,000 and 1:100,000. Membranes were washed 4 times with PTEM then treated 
with DAB and H2O2, a more stable colorimetric HRP substrate. (DAB alone shows a minor color 
change when added to PTEM only equilibrated membrane with no antibody treatment likely due 
to air oxidation.) As demonstrated in figure 3.7, the best blocking was performed using 
10mg/mL sheared salmon sperm DNA producing a solid white membrane at all dilutions. The 
5% BSA was shown to have some background which reduced to essentially no background at a 
dilution of 1:20,000. PTEM alone (no-blocking) gave background noise that was not reduced 
unless only 1:100,000 dilution was utilized. We then repeated the test strips and diluted the 
salmon sperm DNA to 1 mg/mL, 200 µg/mL, 100 µg/mL 50 µg/mL 20 µg/mL and 5 µg/mL (and 
100mg/mL simultaneously) however none of these concentrations demonstrated blocking when 
the secondary antibody was utilized at 1:10,000 (blocking and antibody treatment were for 1 
hour shaking and washed 4 times with PTEM before adding DAB substrate). 
 As such, our first attempt in repeating the northwestern blot was using the 1:10,000 
dilution with 10mg/mL salmon sperm DNA as a blocking agent. (For this and subsequent blots, 
all steps were performed at 4°C while shaking. Sequentially, the membrane was blocked for 2 
hours, washed with PTEM, incubated with Fab 7 as the primary antibody for 3 hours, washed 
with PTEM, and incubated with anti-Fab HRP as the secondary antibody for 2 hours, washed 
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with PTEM and DAB substrate with H2O2 added.  Washing with PTEM was performed at least 4 
times with each washing lasting at least 5 minutes. All antibodies were diluted in blocking buffer 
before use. However, when this was attempted, no result was obtained suggesting that the high 
amounts of DNA saturated the membrane and may have masked the RNA from being detected 
by Fab 7. When the blocking buffer was switched to 5% BSA, a very high resolution with a good 
signal to noise ratio was observed as shown in figure 3.8. We attempted to further optimize our 
results by lowering the dilution of the secondary antibody to 1:20,000, however, only very faint 
bands were detected suggesting that our assay was now sufficiently optimized.  
Sensitivity of the Northwestern Blot 
 Northwestern blot results of a series of sample concentrations were analyzed to determine 
the detection limit and compared to the Stains-All™ staining results. As seen in figure 3.9, 
Stains-All™ is capable of detecting as low as 50 ng of tRNAiMet with confidence whereas the 
Northwestern blot was capable of detecting 10 ng, suggesting that the sensitivity is about 5 fold 
improved over staining. Stains-All™, is capable of detecting all RNAs while the Northwestern 
blot should only be capable of identifying antigens that bind to the Fab utilized as a primary 
antibody. 
Using the Northwestern Blot to Determine Cross-Reactivity of Fab 7 
 With optimized Northwestern blot conditions established, this novel tool allowed us to 
investigate whether Fab 7 will cross-react with other structured RNAs using total RNAs isolated 




 Utilizing a spin column total RNA purification kit, total RNA was purified from MDA-
MB-231 cells, resolved on an 8% native gel, and visualized with Northwestern blot using in vitro 
transcribed tRNAiMet (1 µg) as a control. As shown in figure 3.10, extracted tRNA migrate at the 
same location as the control tRNA in the accompanying gel stained with Stains-AllTM. However, 
there was no apparent band in the Northwestern blot at the same location possibly indicating that 
an insufficient amount of total RNA (20 µg) was loaded. While tRNA abundance varies from 
cell line to cell line, only about 15% of total RNA is tRNA, while yet only a fraction of this is 
tRNAiMet, therefore only sub-nanogram amounts of tRNAiMet or less would expected to be 
observed, which is on the low end of assay detection. However, a signal was detected as a streak 
coming from the well which suggests binding either specific or non-specific to the large RNA 
species, the large and small ribosomal subunits. Alternatively, tRNAiMet normally associates with 
the ribosome so it could be bound or "trapped" in the large ribosomal RNA. 
 Because human tRNAiMet could not be purchased but is similar in sequence to yeast 
tRNAiMet, we wanted to determine if Fab 7 could also bind to it and tRNAiMet from lower 
species. We therefore purchased, purified tRNAiMet from E. coli and the yeast S. Cerevisiea, E. 
coli and yeast total tRNA, and yeast total RNA of unknown quality. From the screen (fig 3.11), 
none of the tRNAs from the other species as either purified tRNAiMet or total tRNA showed any 
signal except for a signal coming from the well of the E. coli tRNAiMet. Since the purification 
method of this E. coli tRNA is not reported, this band is difficult to determine although the most 
likely explanation is non-specific binding to the ribosomal RNAs. The yeast total RNA was 
demonstrated to be highly degraded and did show a faint signal but this was likely due to non-
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specific binding and not at the appropriate location. Total human RNA showed the same result as 
before although there was a possible faint band at the "end of the streak". 
 In the previous experiment the RNAs were extracted and directly run on native gel 
conditions. To see if pre-denaturing RNA made a difference, total RNA was treated with 45% 
formamide or 45% formamide with heating at 90°C for 5 minutes then set on ice. Then the 
samples were run on an 8% native gel. Since tRNAs are robust and known to refold, it was not 
surprising to see that the tRNAiMet control still migrated to a similar location in the gel as that 
under the non-denaturing pre-treatment conditions (stained with Stains-All™) especially since 
there is magnesium in the gel to promote proper folding. Likewise, the Northwestern blot 
demonstrated similar results only this time a new faint band was observed just above the 
tRNAiMet control band (fig 3.12). One hypothesis is that this band is tRNAiMet that was "trapped" 
in the ribosome and then some released under electrophoretic conditions. Alternatively, the total 
RNA extraction kit was designed to extract all RNAs including ones found in the nucleus. Thus 
we hypothesized that this could be pre-tRNAiMet as schematically drawn in figure 3.13. 
 When a tRNA is first transcribed by the RNA Polymerase III enzyme, pre-tRNA is 
formed which has a 5' and 3' overhang that are cleaved by RNAse P and other nucleases 
respectively.37 With some tRNAs, introns must also be removed and in some cases the 3' CCA 
must be added post transcriptionally.37 In addition, individual bases are further modified for 
greater control such as excluding the initiator tRNA from behaving as an elongator tRNA.29,30 
The vertebrate tRNAiMet lacks introns but does require 5' and 3' cleavage and CCA addition, as 
well as 8 base modifications.23,45 As such, the pre-tRNA of tRNAiMet is expected to be slightly 
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larger that mature tRNAiMet. Since Fab 7 was raised against tRNAiMet lacking the 3' CCA, it is 
expected to bind to both mature tRNAiMet and pre-tRNAiMet.  
 Next, total RNA and control tRNAiMet were analyzed with northwestern blot using a 6% 
d-PAGE gel with pre-treatment of 45% formamide with heating at 90°C for 5 minutes then set 
on ice. This gel showed a slightly different banding pattern in the Stains-All™-stained gel but 
produced similar results on the northwestern blot still showing a faint band above the tRNAiMet 
band and a smear coming from the well as shown in figure 3.14. 
 We then utilized a different spin-column RNA extraction kit, designed to remove large 
RNAs and enriching for small RNAs. When checking reactivity of Fab 7 against total small 
RNAs (10 µg), no signal was detected in the northwestern blot (except for a small smear near the 
well), as compared to the tRNAiMet only control (0.5 µg). The corresponding Stains-All™-
stained gel demonstrated a signal in the total small RNA lane that corresponded with the 
tRNAiMet control indicating that tRNAs were present. 
 Since all of the northwestern blots were performed using polyacrylamide gels which are 
only suitable for small RNAs, an agarose northwestern blot was performed in order to observe 
cross-reactivity with the larger RNAs. As seen in figure 3.15, a distinct intense band and faint 
band underneath with streaking were detected near where the ribosomal RNA bands were 
detected after staining with Gel Red. The tRNAiMet control was also observed but the resolution 
was poor due to pore size of the 1.5% agarose gel. The data suggests that either tRNAiMet is able 






 Because antibodies bind to the tertiary structure of macromolecules, cross-reactivity can 
occur where there is high structural homology regardless of the primary sequence. We therefore 
challenged the total RNA isolated from breast cancer cells using a 25mer DNA probe 
complimentary to the last 25 nucleotides in the tRNAiMet sequence starting just before the CCA. 
This sequence is contained in both mature tRNAiMet and pre-tRNAiMet (abundance of this may be 
too low to be detected) so both species should be identified. In vitro transcribed tRNAiMet (with 
CCA) was used as a control next to total RNA and electrophoresed using 6% denaturing PAGE. 
As expected, the probe successfully bound to the control, however using 2 µg of total RNA, no 
signal was observed in the same location as the control (figure 3.16). However there was a faint 
band at the top of the well, where the large ribosomal RNAs aggregate suggesting that we may 
be identifying tRNAiMet trapped within the ribosomal RNAs. Alternatively this could be due to 
binding non-specifically to the ribosomal RNAs. More work is needed to elucidate what is 
actually happening. An agarose gel northern blot that can separate large RNAs will be necessary 
to see if there is a specific band. 
Conclusions 
 To the best of our knowledge, determining the cross-reactivity of RNA binding 
antibodies has not been attempted previously. We present the development of the northwestern 
blot to determine cross-reactivity of RNA-binding antibodies from whole cell RNA extractions 
or other purified RNA species. We also used other methods including a northern blot to elucidate 
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Fab 7 binding to native tRNAiMet. Currently, the results are inconclusive. The combined data 
suggests that tRNAiMet may actually co-migrate with ribosomal RNA, and if this is true, current 
commercial purification methods would be invalid to measure tRNAiMet quantitatively from 
tissue culture extracts. On the other hand, non-specific binding to the ribosome could just be an 
artifact producing false positive results throughout the various assays. 
 However, if it turns out that tRNAiMet is not stuck in the ribosome, lack of identifying 
tRNAiMet in the Northwestern blot could be due to the fact that tRNAiMet has 8 base 
modifications not present in the in vitro-transcribed version that we selected against.  This would 
suggest that the modifications present on mature tRNAs are important for future antibody design 
if they are truly inhibiting the binding of Fab 7. On the other hand, in vitro transcribed tRNAiMet 
was able to be aminoacylated with methionine by the purified human MARS enzyme and could 
be inhibited with Fab 7, suggesting that at least structurally, the in vitro transcribed tRNAiMet is 
similarly folded to the mature tRNAiMet because we would expect the enzyme to detect only 
properly folded tRNAiMet which recognizes the anticodon and CCA in the correct spacial 
orientation. Indeed, the study of tRNAs and other RNA species by in vitro transcription is well 
documented in the literature and has served as a good model. However, due to the specificity of 
antibodies in comparison to enzymes, minor structural modifications could in theory disrupt 
binding to the point of lost function. More work is clearly needed to elucidate the rules to the 
novel emerging field of RNA-binding antibodies. 
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Materials and Methods 
Materials 
E. coli tRNAiMet (#FM-03), and partially charged yeast tRNAiMet (#MI-60) were 
purchased from tRNA Probes. E. coli tRNA was purchased from Sigma Aldrich (# R4251-
100UN). Yeast tRNA was purchased from EMD Millipore (#55714-250MG) and Yeast RNA 
was purchased from MP Biomedicals (# 152026). Protein-A HRP was purchased from BD 
(#610438) and the anti-Human IgG F(ab’)2 ImmunoPure antibody was purchased from Thermo 
(#31482). Protein molecular weights, epsilon, and isoelectic point values were calculated using 
http://web.expasy.org/protparam/ for in-house synthesized proteins or when not provided by the 
manufacturer. 
Cloning, Expression, and Purification of tRNAeMet and tRNAiMet-CCA 
A 3' CCA post-transcriptional modification is needed for detection and aminoacylation 
by the MARS enzyme. Quick Change PCR was utilized to add the CCA nucleotides to the 3' end 
of the tRNAiMet gene using the forward primer 
(CGAAACCATCCTCTGCTACCACGAAGAGAAGCTTGGCG) and the reverse primer 
(CGCCAAGCTTCTCTTCGTGGTAGCAGAGGATGGTTTCG) to the existing tRNAiMet 
plasmid. The reaction was performed with 2.5 units of pfu, 6-100ng of plasmid template, 0.4 µM 
of each primer (20 pmoles), and 0.4 µM of dNTPs in pfu buffer. The reaction volume was set to 
50 µL and the PCR program was 95oC 5 min.; 12 cycles of (95oC 30 sec., 58oC 60 sec., 68oC 12 
min.); 4oC hold. Reactions were verified with 1% agarose gel electrophoresis. 
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The PCR product was digested using 60 units of Dpn I in NEB buffer 4 (50 mM 
Potassium Acetate, 20mM Tris-acetate, 10mM Magnesium Acetate and 1mM DTT pH 7.9) and 
incubated at 37°C for 3 hours. The digested PCR product was then cleaned up using the PCR 
clean up kit (catalog) by the manufacturer’s instructions eluting in 50 µL elution buffer. The 
DNA was then concentrated 5 fold and transformed into JM109 chemically competent cells by 
heat shock transformation. JM109 cells were then amplified and plasmids purified using a 
standard midi prep kit (Qiagen QIAprep® Spin Miniprep Kit #27106) transcription 
Electrophoretic Mobility Shift Assay 
tRNAiMet (20 pmoles) RNAs, were folded in 6.5 mM Tris pH 7.5, 25mM MgCl2 and 150 
mM NaCl by incubating at 50°C for 20 min and 10 min at RT. Then a 1.5 molar ratio of Fab 7 or 
mock (Tris pH 7.5) was incubated at RT for a half hour. The folded RNA was electrophoresed 
on a 8% native polyacrylamide gel (29:1 bis:acrylamide, 5 mM MgCl2, 89 mM Tris base, 89 mM 
Boric acid) in 0.5x TB running buffer for 70 min at 120 volts. Gels were stained with Stains-
AllTM for 10 min and destained with a high intensity light source before imaging. 
Filter Binding Assay 
2 µL32P labeled tRNAiMet, tRNAeMet, and VCII66 (between 140 and 650 kpcm) was 
diluted in 4546 µL binding buffer (1x PBS, 0.1 mM EDTA, 10 mM MgCl2) and folded by 
incubating for 10 min at 50°C followed by an additional 10 min at RT. To the folded RNA, 130 
μL 40 mg/mL heparin was added as a competitor and 2 µL RNase inhibitor was added to inhibit 
RNA degradation. Serial dilutions of Fabs were made starting at 20 µM and diluted to as low as 
39 nM in 1x PBS. 36 µl folded cognate RNA was added to 4 µl of diluted Fabs for each 
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concentration and incubated shaking for 30 min at RT. Both the Nylon and nitrocellulose 
membranes were equilibrated in binding buffer for at least 15 min prior to use and assembled in 
the filter binding apparatus with the nitrocellulose membrane on top. Fab-RNA mixtures were 
applied to the filter binding apparatus under high vacuum with 100 µL cold binding buffer added 
just before and after the addition of the mixture under high vacuum. After all samples were run, 
an extra 5 min of vacuum was applied, then membranes were air dried for 15 min, exposed to a 
PhosphorImager screen, scanned by Phosphoimager SI (Molecular Dynamics), and quantified by 
ImageQuant (Molecular Dynamics). Binding affinities were calculated by fitting the data to the 
equation: fraction bound = M × [Fab]n/(Kd 
n + [Fab]n), where Kd is the binding constant, M is the 
maximum fraction of RNA bound at the highest Fab concentration, and n is the Hill coefficient. 
Each binding assay was carried out at least in duplicates. 
Aminoacylation Assay 
tRNAiMet-CCA (8 µM during) was pre-incubated with Fab 7 (12 µM ), 4D5 Fab (12 
µM) or mock ddH2O for 30 min at RT in a total of 10 µL. The tRNA and Fab solutions were 
then incubated with 2 µg of MARS per reaction (40 µg/mL) with 0.2 mg/mL nuclease free BSA, 
200 µM ATP, 1mM L-methionine, and 2U/mL inorganic pyrophosphatase in aminoacylation 
buffer (50mM Tris-HCL buffer, 20mM KCl, 10mM MgCl2) in a total of 50 µL for 1 hour at 
37°C and then at RT overnight. Then 100µL of malachite green solution (Echelon # K-1500) 
was added to the reaction and incubated at RT for half an hour, transferred to a 96 well plate and 
read at λ620 on an absorbance plate reader. For background, each reagent (except for the MARs 
enzyme) was tested with the malachite green solution for 30 minutes at RT to identify potential 





MDA-MB-231 and SK-BR-3 breast cancer cells were maintained in high glucose DMEM 
supplemented with 10% FBS and Penicillin (100 IU/mL) / Streptomycin (100µg/mL) at 37°C in 
an environment with 5% CO2. Cells were subcultured in a ratio of 1:3 approximately every 3-5 
days. 
Extraction and Purification of RNAs 
Total RNA was extracted using the Exiqon miRCURY™ RNA Isolation Kit - Cell & 
Plant or Fisher SurePrep™ TrueTotal™ RNA Purification Kit according to the manufacturer’s 
instructions. Small RNAs were extracted using the SurePrep™ Small RNA Purification Kit 
according to the manufacturer’s instructions. RNA concentration was determined by UV-vis 
spectroscopy by determining the absorbance of A260-A320 and assuming 1 absorbance unit = 
40µg/mL RNA. 
Northwestern Blot 
The RNAs tRNAiMet (1 µg) and tRNAeMet (1µg) were folded (- 2 µL 40 µM RNA- 13 µL 
10mM Tris pH 7.5- 2 µL 250mM MgCl2- 3 µL 1M NaCl Incubate for 20 min @ 50ºC)Incubate 
for 10 min @ RT) and electrophoresed in native polyacrylamide gel electrophoresis conditions 
for 70 minutes at 120V. RNAs were transferred onto Hybond N+ membranes for 16 hours at 
25V at 4°C. The membrane was then transferred into blocking solution (5% nuclease-free BSA 
w/v in PTEM) for 2 hours shaking at 4°C. Fab 7 as a primary antibody was then added in 
blocking solution at a concentration of 100nM for 3 hours 4°C. The membrane was then washed 
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with PTEM 4 times for 5 minutes each time shaking. The 2’ anti-Fab-HRP antibody was then 
added at a concentration of 1:10:000 in blocking buffer for 2 hours shaking at 4°C. The 
membrane was then washed with PTEM 4 times for 5 minutes each time shaking. DAB 
tetrahydrochloride solution (0.5mg/mL in 25mM Tris pH 7.2-7.5 with 0.01% hydrogen peroxide) 
was then added to the membrane at RT for about 5 minutes to resolve the blot. 
Northern Blot 
0.5 µg of tRNAiMet and 30µg of total RNA extracted from SKBR3 cells in 50% formamide were 
electrophoresed on a 6% polyacrylamide urea denaturing gel at 100V for 70 minutes. RNA was 
then transferred at 4°C for at least 16 hours at 25V in 0.5X TBE onto a Hybond N+ membrane. 
The membrane was then probed with the complimentary 3’tRNA probe (pmols/heat 10µL) for 
2.5 hours in 10mL of 50°C pre-warmed binding buffer (0.25M Na2HPO4, 1 mM EDTA, 1% 
nuclease-free BSA, 7% SDS), washed 3 times with binding buffer, dried, exposed to a phosphor 
screen, and scanned by  Phosphoimager SI. 
SPR Kinetic Binding Analysis 
The binding affinity of tRNAiMet to biotinylated Fab 7 was determined by surface 
plasmon resonance using a Reichert SR7500DC SPR instrument. Biotinylated Fab 7 was 
captured over the sample channel only on a Planar NeutrAvidin slide (Reichert # 13206065) at a 
concentration of 9.85 μg/mL. 437 micro refractive index units (RIU) were captured. Data were 
collected by injecting dilutions of tRNAiMet (in PEM buffer) over the sample and reference 
channels at 35 µl/min in duplicate. The tRNAiMet in PEM buffer association time was 2 minutes 
and dissociation time was 3 minutes at concentrations of 60.7 nM, 30.4 nM, 15.2 nM, and 7.59 
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nM respectively. After each sample injection, the surface was regenerated with 2 M NaCl for 45 
seconds. The data were double referenced using the reference channel along with buffer blank 
injections and then fit to a Bivalent (2:1) binding model in TracedrawerTM.  Association and 
dissociation rate constants were obtained along with the Equilibrium Dissociation Constant (KD). 
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Figure 3.1. Comparison of the sequence of Human initiator tRNA and human elongator tRNA. 
Human initiator tRNA has 8 base modifications. The A1-U72 base pair in initiator tRNA 






Figure 3.2. Gel shift assay demonstrating that Fab 7 can only cause a shift in human initiator 
tRNA migration , but not purified P4P6 RNA, a mixture of tRNAs isolated from from E. coli, or 
elongator tRNA. Streaking in lane 4 was caused by non-specific binding which was eliminated 
when heparin was added to the sample. Lane 1: tRNAiMet; Lane 2: tRNAiMet + 1.5 eq. Fab 7; 
Lane 3: P4P6 RNA; Lane 4: P4P6 + 1.5 eq. Fab 7; Lane 5: E. coli tRNA mixture; Lane 6: E. coli 









Figure 3.4. Schematic of mature tRNA. Methionyl tRNA synthetase (MARS), like other tRNA 
synthetases, recognizes the anticodon and the 3’CCA extension in order to anneal methionine to 




Figure 3.5. Aminoacylation Assay. Malachite green was used to measure inorganic phosphate 
when an aminoacylation reaction was coupled to an inorganic pyrophosphatase reaction. Fab7 
significantly inhibits charging of initiator tRNA with methionine while a control fab 4D5-KO 
does so to a much lesser extent. Negative control lacking MARS enzyme shows a small signal 




Figure 3.6. Northwestern blot using Protein A-HRP as the secondary (substituted for 2’ 
antibody) only resolves initiator tRNA as a reverse image. b.) Duplicate native gel stained with 





Figure 3.7. Comparison of different dilutions of Anti-Fab-HRP on Hybond N+ membrane 




Figure 3.8. a.) Northwestern blot using Anti-Fab-HRP as the secondary antibody only resolves 
initiator tRNA. b.) Duplicate native gel stained with Stains all™ can not distinguish between 




Figure 3.9. a.) Sensitivity of northwestern blot under optimized conditions compared to b.) a 




Figure 3.10. Northwestern blot examining potential cross-reactivity of Fab 7 with total isolated 
RNAs using native gel conditions. Lane 1: tRNAiMet; Lane 2: 20 µg Total RNA extracted from 




Figure 3.11. a.) Northwestern blot examining potential cross-reactivity of Fab 7 with 
commercially isolated RNA species on native gel running conditions. b.) high molecular weight 
bands b.) duplicate gel loading stained with Stains All™. Lane 1: 0.5 µg isolated E. coli 
tRNAiMet; Lane 2: 0.5 µg isolated S. cerevisiae yeast tRNAiMet; Lane 3: 10 µg total isolated S. 
cerevisiae yeast tRNA; Lane 4: 10 µg total isolated Candida utilis yeast RNA; Lane 5: 10/20 µg 
isolated total human RNA; Lane 6: 0.5 µg in vitro transcribed tRNAiMet-CCA; Lane 6: 10 µg 




Figure 3.12. Northwestern blot examining potential cross-reactivity of Fab 7 with total isolated 
RNAs pre-denaturing before running on native gel conditions. Lane 1: tRNAiMet in 45% 
formamide + heating at 90C for 5 mins; Lane 2: tRNAiMet in 45% formamide w/o heating; Lane 
3: 20 µg Total RNA extracted from MDA-MB-231 cells in 45% formamide + heating at 90C for 






Figure 3.13. Schematic of pre-tRNA. After tRNA is transcribed from the DNA, it contains a 
long 5’ and short 3’ overhang. RNase P cleaves the 5’ end while other endonucleases release the 
3’ extension and then further processing adds “CCA” to the 3’ end. Some tRNAs even contain 





Figure 3.14. a.) Northwestern blot examining potential cross-reactivity of Fab 7 with total 
isolated RNAs running on urea denaturing gel conditions. b.) duplicate gel stained with Stains 
All™. Lane 1: tRNAiMet in 45% formamide + heating at 90°C for 5 mins; Lane 3: 20 µg Total 




Figure 3.15. a.) Northwestern blot examining potential cross-reactivity of Fab 7 with total 
isolated RNAs running on a horizontal 1.5% agarose gel to resolve high molecular weight bands 
b.) duplicate gel loading using a horizontal gel and stained with GelRed™ imaged under UV 




Figure 3.16. a.) Northern Blot exposure showing probing with a 3’ tRNAiMet complimentary P-
32 labeled deoxynucleotide probe. b.) duplicate urea denaturing gel stained with Stains All™. 
Lane 1: 0.5 tRNAiMet; Lane 2: 30 µg total RNA from SK-BR-3 cells. 
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CHAPTER 4: ATTEMPTED DELIVERY METHODS FOR ANTIBODIES 
TARGETING INTRACELLULAR RNAS 
Introduction 
Cancer and other diseases often have markers that distinguish them from healthy tissues. 
Some of these markers such as the Human Epidermal growth factor Receptor 2 (Her-2 receptor) 
on the surface of breast cancer cells are also involved in directly promoting disease progression 
and poor prognosis.1 While many of these markers are found on the cell surface, the bulk of 
disease markers are found inside of the cell where they are not easily accessible to extracellular 
therapeutic proteins. In many human diseases, proteins and structured RNAs are often 
upregulated or aberrant as in cancer, which can cause alterations in cell cycle controls leading to 
disease progression.2-4 For example, tRNA was shown to be overexpressed in breast cancers and 
overexpression of tRNAiMet specifically was shown to promote increased cell proliferation.5,6 
Synthetic antibodies are a class of therapeutic proteins that can be made to specifically 
target over-expressed/aberrant proteins and structured RNAs.7,8 They may be able to directly 
neutralize the overexpressed biomolecules by disrupting their interactions with other 
biomolecules, or can be used as delivery agents for drugs that target the specific macromolecules 
as demonstrated in figure 4.1.9,10 Antibodies, like other therapeutic proteins are generally unable 
to penetrate the cell surface and reach their targets without assistance from delivery vehicles 
when their targets are intracellular.4 Indeed, the mammalian cell has evolved the ability to tightly 
control which molecules may enter and exit the cell. 
89 
 
Previously, we selected an antibody, Fab 7, which has been demonstrated to bind to in 
vitro transcribed tRNAiMet. Additionally, this antibody was shown to disrupt the protein 
translation process in vitro presumably by binding tRNAiMet and inhibiting the initiation step of 
protein synthesis. Disruption of protein synthesis is predicted to reduce cancer cell growth.11 
While the in vitro data shows promise for Fab 7 to behave as a therapeutic biomolecule, its target 
tRNAiMet is an internal cell target thus delivery of this antibody into cancer cells is critical for its 
efficacy if it is to be used as a therapeutic drug. 
To this day, there is still no optimal way of delivering therapeutic proteins into cells in 
high quantities.12-14 However, since pathogens such as whole viruses and microbes can gain entry 
into mammalian cells and survive and reproduce, this suggests that they are good models for 
exploiting cellular entry and that future delivery of therapeutic proteins is entirely possible. The 
next section will review the methods of pathogen entry into cells, and then proceed with our 
group's attempts to mimic these interactions to gain entry into cancer cells. 
This first method involves receptor mediated endocytosis as shown in figure 4.2, and is 
common among many viruses. Influenza, the virus that causes the flu as an example, expresses a 
glycoprotein called hemagglutanin (HA) that binds to cells that express sialic acid-containing 
receptors on the cell surface such as upper respiratory cells.15 Once the virus binds the receptor, 
this signals the cell to endocytose the virus and acidification of the endosome then begins.15 As 
the pH drops, the membrane of the virus (the viral envelope) fuses with the endosomal 
membrane and the HA glycoprotein alters its conformation promoting endosomal escape where 
the virus now has access to the intracellular machinery of the cytosol including the ribosomes.15 
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Likewise, cancer cells often overexpress certain receptors that can be valuable targets. 
Ovarian cancers for example are known to overexpress folic acid receptors and many breast 
cancer cells overexpress the Her-2 receptor.1,16 Already, a therapeutic drug, brand name 
Herceptin (Trastuzumab) is an antibody that binds to the Her-2 receptor.9,17 When the antibody 
binds, it crosslinks and internalizes the receptor via endocytosis, blocking its natural ligand from 
binding and permitting cell growth.1 Although endosomes containing Her-2 are typically 
recycled back to the cell surface or are acidified and delivered to lysosomes for degradation, the 
drug has still been largely successful primarily due to antibody-dependent cell cytotoxicity 
(ADDC).18 While this particular mechanism involves reducing availability of ligand binding as a 
means of reducing cancerous growth, being able to permit endosomal escape of an antibody 
could facilitate a new class of drugs if a drug or biologic is successfully endocytosed. 
In this model, an antibody is designed to bind to the external cell surface receptor that is 
tethered to a cargo such as a small molecule drug or another antibody specific to an internal 
target thus we can refer to this as a bi-specific antibody.10,19 The antibody-drug or bi-specific 
antibody is then internalized via receptor-mediated endocytosis. Adding an additional component 
that can assist in endosome disruption should allow for successful endosomal escape and the 
therapeutic synthetic construct to enter the cytosol where it can perform its intended function.20 
Chloroquine for example is a reagent that can be used to help selectively permeabilize endocytic 
compartments.20 Ideally, adding a pH sensitive membrane disrupter as occurs with influenza 
could indeed help overcome the current difficulty in endosomal escape.15 In our case, we 
synthesized the Fab monomer of Trastuzumab (4D5) and tethered it to Fab 7, where 4D5 is the 
delivery arm or “shuttle” and Fab 7 is the therapeutic arm or “cargo”. 
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Besides having specificity for certain cell types and ability to enter the cytosol, viruses 
are different from antibodies and other receptor binders in that they have high valency in 
addition to their specificity.21 An individual therapeutic molecule such as Trastuzumab only has 
a valency of 2 per molecule in that it contains only two Fabs with which it can detect cell surface 
receptors on target cells.1 Viruses particles on the other hand contain a larger surface area that 
can support multiple expressed antigens simultaneously that can bind to the target cell 
receptors.21 This creates an avidity affect in addition to having affinity to the receptor ensuring 
multiple attachment sites of the virus to the target cell much like Velcro functions in order to 
improve adherence as shown in figure 4.3.21 
One synthetic approach to creating a multivalency affect is to utilize nanoparticles as 
delivery vehicles where multiple therapeutic molecules of the same kind or a heterogeneous 
mixture can be simultaneously displayed on the nanoparticle to improve binding efficacy.22,23 
We identified quantum dots (QDs) as ideal nanoparticles for attachment since their small size 
should still permit endocytosis, they permit multiple attachment sites for therapeutic molecules, 
and due to their highly fluorescent properties, they can also be used to detect cellular entry of the 
entire construct.23 As such, QDs are simultaneously therapeutic delivery vehicles and reporters. 
We chose to synthesize copper indium sulfide (CuInS) based QDs due to their reduced toxicity 
compared to cadmium sulfide (CdS) based QDs and their red shifted fluorescence spectral 
properties which reduces autofluorescence when used in tissue culture.24 
Another strategy used by viruses to gain entry into cells is to use a cell penetrating 
peptides (CPP).13,25 The HIV virus enters cells similarly to that of influenza, first binding 
primarily to CD4+ T immune cell surface via its GP120 surface protein antigen.26  However HIV 
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has another trick to improve its infectivity. It contains a protein that has a cell penetrating 
component called Trans-Activator of Transcription (TAT).27 This protein is secreted by the 
infected host cells and is then internalized by neighboring cells which contributes to increased 
infectivity by weakening immune functions and promoting apoptosis of other immune cells.27 It 
turns out however, that only residues 48-60 of the TAT protein referred to as the TAT peptide is 
sufficient to enter cells.13 Currently the mechanism of how the TAT peptide penetrates cells is 
still under debate, however it is highly positively charged and has been shown to bind to heparan 
sulfate on cell surfaces.27 TAT peptide has been shown to be sufficient to permit entry of 
therapeutic proteins into cells primarily by expressing it as a fusion protein.28,29 TAT, however 
can only be utilized in relatively small doses to deliver proteins due to its multiple transactivating 
effects that weaken or induce apoptosis in the cell.25,27,29 
There are three main groups of CPPs.13 The first group are peptides derived from protein 
transduction domains that includes TAT, Penetratin, Transportan, and VP22.13,30 The second 
group of CPPs is composed of amphipathic peptides that are primarily synthetic including MAP, 
KALA, MPG, and Pep-1.13 The third group is composed of CPPs that do not fit in either of the 
first two categories and several of them contain highly positively charged peptides such as poly-
arginine and dendrimer-like molecular scaffolds including loligomers.13 
Pep-1 is available commercially under the name ChariotTM, and is composed of 3 
domains: a hydrophilic positively charged domain presumably for enhanced cell binding and 
improved solubility, a hydrophobic domain for binding to membrane lipids, and a linker region 
for linking the two functional domains together.31,32 Pep-1 was reported to have low toxicity in 
cell lines tested, including negligible toxicity even at 100 µM and does not require expression as 
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a fusion protein as with other CPPs like TAT.31 Pep-1 can be directly incubated with a protein of 
interest and uses non-covalent interactions (presumably hydrophobic interactions) to deliver 
proteins into live cells.31 Additionally, Pep-1 has also been shown successfully be utilized as a 
fusion protein to deliver Super Oxide Dismutase 1 (SOD1), Heat Shock Protein 27 (HSP-27), 
and other large proteins into cells although this work has only been performed by a few research 
groups.33-38 We therefore first attempted to use Pep-1 to deliver Fab 7 into breast cancer cells as a 
non-covalently bound complex and then later as a fusion protein. 
We now present the results of the synthesis of the constructs and the attempted delivery 
methods as described above. We will then discuss the challenges and lessons learned from 
several of our attempts at delivering Fab 7 into cancer cells. 
Results and Discussion 
Synthesis of the Bispecific Fab and Biotinylated Fabs for Attachment to Quantum Dots 
Synthesis of C-terminal Cys Mutants of Fab 7 and Fab 4D5 
 Topology is important for cellular delivery of a therapeutic molecule. In order to make 
the antigen binding end of a Fab accessible to the antigen and create specific labeling via thiol 
chemistry, a cysteine was introduced by Kunkel mutagenesis at the C-terminus of the heavy 
chain. This location is ideal in that it is freely available, hence reactive, and this region is far 
from the antigen binding site of the Fab.39 While Fabs do contain cysteines, all of them are 
paired.40 Disulfide bonds are found within each chain to assist with proper folding, and one is 
found between the light and heavy chain tethering them together covalently in our construct.40 
As such, Fabs do not naturally have a free cysteine available for forming disulfide bonds with 
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other free thiols, and reduction of these internal thiols may disrupt Fab tertiary structure and 
hence antigen binding.40 
 Both Fab 7 and 4D5 Fab were mutated to contain the C-terminal cysteine amino acid. 
After transforming electro-competent 34B8 cells with the respective Kunkel plasmids, both Fabs 
were found to express in reasonable yields and Fab 7 Cys was able retain its binding affinity to 
tRNAiMet in the filter binding assay. However as shown in Figure 4.4, Fab 7 Cys expressed 
primarily as a 100 kD band (fractions 12-18) and the expected 50 kD band was only present in 
low amount (fractions 10-11) as indicated by SDS-PAGE after cation exchange. The intense 
band at 100 kD can be attributed to the formation of Fab dimers, which is not surprising given 
the degree of freedom of the C-terminal cysteine residues. The lack of steric hindrance may have 
permitted assembly of Fab dimers using the same periplasmic machinery that normally forms the 
disulfide bonds between the light and heavy chains of the Fabs in 34B8 cells. As such, we have 
showed that the C-terminus cysteine of the heavy chain is “too reactive” and unsuitable for the 
production of Fab monomers. Similar results (not shown) were obtained with 4D5 Cys with 
slightly lower yields. 
Reduction of the Fab Dimers 
 Since the C-terminal Cys Fabs were thought to be fully intact and simply dimerized, we 
thought that we might be able to selectively reduce the Fab dimers into their individual Fabs by 
using selective reducing agents. Both 2-mercaptoethylamine (2-MEA) and tris(2-
carboxyethyl)phosphine (TCEP) are known to have a preference for freely available disulfide 
bonds over other reducing agents such as Betamercaptoethanol  (β-Me) and Dithiolthreitol 
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(DTT).41-43 However as shown in figure 4.5a-b, neither 2-MEA nor TCEP were able to 
selectively reduce the 4D5 Cys Fab dimers into Fab monomers without disrupting the light and 
heavy chain intermolecular disulfide bond as indicated by the 50 kD fragments and 25 kD 
fragments respectively by SDS-PAGE. Furthermore, it is unclear if intramolecular disulfide 
bonds in the individual Fab heavy and light chains were disrupted. Nearly identical results were 
also obtained with Fab 7 Cys (data not shown) with “over-reduction” occurring. 
Since 2-MEA, however, was able to reduce nearly all of the Fab dimers as indicated by 
the disappearance of the 100 kD fragment at a concentration of 500 µM that was not observed 
with TCEP, we treated 4D5 Cys dimers with a range of 100-500 µM to further identify the 
optimal concentration needed to completely eliminate Fab dimers as shown in figure 4.5c. 
Although possible, separation of the intact Fabs from the light and heavy chain monomers would 
still be challenging with size exclusion chromatography due to the small difference (25 kD) in 
molecular weight and yields would be lower with an increased purification step. Combined with 
the previous results, the data suggests that the intermolecular disulfide bond between the heavy 
and light Fab chains was similarly as reactive as the C-terminal disulfide bonds between Fab 
dimers toward reducing agents. 
 Intriguingly, when the amount of protein loaded on the gel was increased to about 20.5 
µg during the reduction experiments (Fig 4.5) compared to the eluted fractions after cation 
exchange (approximately in the low µg to high ng range) as shown in figure 4.4, 75 kD 
fragments were also evident suggesting the formation of heterotrimeric Fab chains. Based on the 
schematic in figure 4.6, these 75 kD fragments are likely composed of one light chain linked to 
two heavy chains or one heavy chain and two light chains, although homotrimeric heavy chains 
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could also exist but are far less feasible due to stoichiometric ratio. Furthermore, through either 
conjugation during Fab expression or reduction of the heterotrimeric chains of Fab dimers by one 
of the reducing agents, the existence of homodimeric heavy chains and homodimeric light chains 
are also possible but indistinguishable from the normal Fabs on SDS-PAGE and are likely non-
functional in tRNAiMet antigen binding. Thus, although we could control the stoichiometry of the 
reducing agents, we could not control the stoichiometry of the heavy and light chain synthesis 
and ultimately the correct composition of the Fabs. We therefore decided to explore other 
locations on the Fab to engineer a cysteine residue that would be available for reaction of small 
molecule linkers while mildly hindered to prevent the construction of Fab dimers. 
Synthesis of A121C Fab 7 and Fab 4D5 
A literature search was performed to see if there was already an ideal site identified in the 
Fab framework region (the region that does not contain the CDRs) that would permit the 
expression of Fab with a free cysteine without disrupting Fab structure. Such a site should be 
solvent exposed, somewhat sterically hindered to prevent enzymatic formation of dimers but not 
too much as to prevent future conjugation via chemical linkage. Through extensive literature 
searching, a peer reviewed manuscript was identified that had tested several cysteine mutations 
in the Fab framework region and the ability of these mutations to be expressed and form 
disulfide bonds with other molecules.44 Surprisingly, no Fab dimers were reported. We learned 
that mutating alanine 121 to cysteine (A121C) was shown to be available for chemical coupling 
but did not form dimers based on its orientation and expressed solely as Fab monomers.44 As 
such, we used Kunkel mutagenesis to induce this same point mutation in both Fab 7 and 4D5. As 
shown in figure 4.7, both Fab 7-A121C and 4D5-A121C were able to express in moderate yields 
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with >90% purity after affinity and cation exchange chromatography. Minor bands included light 
and heavy chain monomers as indicated by the 25 kD bands and 15 kD heavy chain fragments 
with retained protein A affinity from either selective protease activity or truncated synthesis. 
Synthesis of the Bispecific Fab 
In order to produce bi-specific Fabs, we chose a bi-functional linker that would react 
specifically with the free cysteine sulfhydryl of Fab 7 A121C and surface amino groups of the 
4D5 Fab. The linker [SM(PEG)2 Thermo #22104] we chose has 3 components: a reactive N-
hydroxysuccinimide (NHS)-ester on one end that selectively reacts with free amines between a 
pH of 7 and 9, a polyethylene glycol (PEG) linker which promotes flexibility and solubility of 
the molecule, and a maleimide functional group on the other end that selectively reacts with free 
thiols at a pH between 6.5 and 7.5 (fig 4.8) according to the manufacturer’s literature. The PEG 
portion was available at different lengths. A size of 4 PEG units was chosen to give some degree 
of flexibility but not too long as to reduce the overall size of the molecule for higher success of 
entry into cells. The NHS-ester was first reacted to random amines present on Fab 4D5 surface 
and then excess linker removed by dialysis. Then the maleimide on the other side of the linker 
was then reacted to the free thiol on Fab 7. We chose Fab 7 to have the specific linker over 4D5 
because Fab 7 is in theory the drug “cargo” being delivered by the 4D5 “shuttle.” Based off the 
stoichiometry, it may be possible to attach multiple Fab 7 Fabs to a single 4D5 Fab, thus one 
“shuttle” could contain more than one “cargo” which is theoretically more ideal than the reverse. 
As observed in figure 4.9, indeed, the bulk of 4D5 was bound to either one or two Fab 7 units as 
evidenced by the 100 kD and 150 kD bands. Even small amounts were found to have 3 bound 
Fab 7 units as indicated by the faint 200 kD bands.  
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Biotinylation of Fab 7-A121C 
Both Fab 7 A121C and 4D5 A121C can also be selectively biotinylated using a similar 
linker to the bi-specific Fab which can then bind to streptavidin coated surfaces such as QDs. 
The linker (EZ-Link® Maleimide-PEG2-Biotin Thermo #21901) that was chosen to biotinylate 
Fab 7 A121C and 4D5 A121C contains the maleimide group for binding to the free cysteine 
thiol, a PEG linker of 2 units, and a biotin (figure 4.10) which was reacted according to the 
manufacturer’s protocol. Therefore each biotinylated Fab contains exactly one biotin and in a 
specific location. As shown in figure 4.11, Fab 7 was successfully biotinylated using the linker as 
demonstrated by the bead-pull down assay. The assay functions by incubating increasing 
concentration of streptavidin beads with a biotinylated moiety, and then retrieving the 
supernatant and checking in this case for any remaining protein. As the amount of streptavidin 
beads was increased and there was no remaining protein in the supernatant, the reaction was 
considered complete and all the Fab 7 was biotinylated. The results were the same for the 
biotinylation of Fab 4D5 A121C. 
Preparation of Materials for Cell Culture Experiments and Preliminary Cell Culture Results 
FITC Conjugation of 4D5, Cell Staining, and Sonfocal Microscopy 
Before conjugating the biotinylayed Fabs to quantum dots freshly pre-coated with 
streptavidin, the 4D5 Fab was conjugated with FITC to confirm its entry into Her-2 positive 
cells. 4D5 Fab actually has several variations that all bind to the Her-2 receptor. Of the 9 
reported Fabs, we chose 4D5-2, 4D5-4, and 4D5-8.45 The 4D5-4 Fab is the specific 4D5 Fab that 
we have used previously and was chosen because its structure is known, and has excellent 
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binding affinity. 4D5-2 had reduced binding affinity but did not alter cell growth like the higher 
affinity binders.45,46 4D5-8 is the Fab from authentic Trastuzumab.45 All three 4D5 Fabs were 
conjugated with FITC (Fig 4.12). Cells were then fixed and treated with the 4D5 Fab overnight 
at various concentrations. Unfortunately, none of the Fabs appeared to bind. We then attached 
FITC to the 4D5 Fabs with no Fab 7 attached to verify binding of 4D5 Fabs to SK-BR-3 and 
L3.6pL Her-2 positive cancer cells. However, binding was not observed. We later learned in an 
interview with Christoph Spiess from Genentech, the creators of 4D5, that 4D5 must have 
multivalency such as in its IgG form in order to crosslink the Her-2 receptor to bind and promote 
internalization of 4D5.47 Since our Fabs are only monovalent, this likely explains why we were 
unable to see labeling of the receptors with the the control FITC labeled 4D5 Fabs. As such we 
decided to change strategies to using Quantum Dots which permit multiple Fabs on one QD 
shuttle. 
Synthesis of Copper Indium Sulfide Quantum Dots 
Since Quantum dots are excellent imaging tools and can be surfaced modified to add 
biomolecules, we chose to use them as a model to deliver multivalent Fabs into cells.48 By the 
schematic in figure 4.13, we can expect that one QD can accommodate both a surface 
recognition “delivery” Fab in this case 4D5 to home in on Her-2 receptors, and a target “cargo” 
Fab, in this case Fab 7 to disrupt protein synthesis. 
Quantum dots typically consist of a core containing a heavy metal and a shell that 
encapsulates the core and improves quantum yield.48 Sometimes QDs are ‘doped’ with other 
metals such as manganese to alter the fluorescent wavelength.49 Most commercially available 
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quantum dots used for imaging consist of Cadmium such as Cadmium Selenium with a Zinc 
Sulfide Shell.50,51 The QDs are then surface modified to make them ‘biofriendly’ and water 
dispersible such as coating with streptavidin.51  While very bright and typically grow bight 
orange like that of ethidium bromide, their preferred excitation is in the UV range, not ideal for 
live cell imaging.50 Furthermore cadmium is among the most toxic of heavy metals which 
promotes toxicity in live animals where the toxic metal is accumulated in the liver.52,53 Cadmium 
based QDs may also be toxic to cell culture depending on the type of QD coating used and time 
frame of the experiment.53 As such we chose to synthesize Copper Indium Sulfide based 
quantum dots with a Zinc Sulfide shell, where the indium and copper metals are known to be far 
less toxic than cadmium.24 Additionally, they were chosen because of their ability to emit light in 
the far red and infrared spectrum, which is most ideal for tissue samples where autofluorescence 
is a problem at the lower wavelengths.24 
Using a previously described method, we utilized a temperature controlled synthesis of 
high quantum yield CuInS/ZnS QDs.24 The synthesis of the core contained two main steps. The 
first was pre-mixing copper iodide and indium acetate in DDT at around 100°C until a clear 
yellow liquid with white clumps formed which took about 15 minutes.24 Once observed, the 
reaction was then set to 230°C and core crystal growth was observed by observing a color 
change which occurred at around 190°C.24 The color of the solution red shifted starting from 
yellow with time until an almost black clumpy solution formed (figure 4.14). By altering the 
time of core crystal growth permitted change in QD color and emitted wavelength. Varying the 
molar ratio of copper acetate to indium sulfate also altered the emitted wavelength where an 
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equal ratio largely produced red emitting QDs and a higher ratio was blue shifted into the orange 
emitting range.24 
The core QDs alone were very bright but had relatively low quantum yields compared to 
the commercial cadmium based QDs. Adding a zinc sulfide shell to the CuInS core QDs 
permitted increased quantum yield but caused a blue shift (figure 4.15). Thus when synthesizing 
CuInS QDs, it is important to determine whether emitted fluorescence wavelength or quantum 
yield is more desirable for its particular application.  
Using Chariot to Deliver Fab 7 Into Cancer Cells 
Chariot™ is a commercially available synthetic cell penetrating peptide (CPP) that 
contains a hydrophobic membrane binding region, a linker, and a highly positively charged 
hydrophilic region that is thought to bind to the cell surface and promote pore formation in the 
cell membrane.31,32 Chariot™ is also known as the peptide Pep-1 and is one of many 
commercially available cell penetrating peptides utilized for protein cell delivery studies.31 The 
mechanism in which Pep-1 is able to bind to a protein of interest is unclear, however current 
evidence suggests hydrophobic interactions between the protein and the CPP.31 While other 
CPPs are available such as HIV Tat and Antennopoedia peptide, they have had known issues 
such as toxicity, or unfolding of the peptide cargo.13,25,30 
When Pep-1 was used to deliver Fab 7 into cancer cells by the manufacturer’s 
instructions, no change in cell viability occurred (data not shown). This is likely because only 
200 nM (1 µg) of Fab 7 was utilized per delivery which is unlikely to produce an effect at this 
low an amount especially if delivery is not 100% efficacious.  After talking to the manufacturer 
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and reviewing the product literature, roughly a ratio of 1:1 by weight of protein to Pep-1 was 
recommended for optimal performance. We then scaled up amounts of both protein and Pep-1 
accordingly and tested the toxicity of Pep-1 at these higher concentrations. The original literature 
reported that 100 µM of Pep-1 was essentially non-toxic in several cell lines however this was 
not found to be true for our cell lines.31 We therefore tested Pep-1 toxicity in HEK 293 cells, one 
of the cell lines reported in the original paper by Morris et. al.31 As demonstrated in figure 4.16, 
100 µM was found to be extremely toxic which is not in agreement with the manufacturer’s data. 
Cell culture variability from lab to lab may have attributed to these differences. 
We then used a maximum concentration of 25 µM Pep-1 to deliver a maximum of 1.49 
µM of Fab into SK-BR-3 cells. With a molar ratio of Pep-1 to protein of 16.8:1, the 
stoichiometry significantly limits the amount of Fab that can be delivered before Pep-1 begins 
exerting its cytotoxic effects. Nonetheless, we were able to show a difference between cells 
treated with 25 µM Pep-1 delivering 1.49 µM of Fab and cells treated with 25 µM Pep-1 only 
(figure 4.17). The experiment was performed in duplicates with low error. However these results 
were not reproducible after switching to a new lot of Pep-1. Other users of the product have 
reported differences from lot to lot. Due to the high toxicity of Pep-1 in multiple cell lines 
combined with uncertainty about the quality of the product, we decided not to proceed with using 
Pep-1 as a delivery agent. 
Synthesis of a Pep-1 Fab 7 fusion protein 
While Pep-1 is known to deliver protein cargo by non-covalent interactions, we found 
several peer-reviewed manuscripts from research groups in Korea and China that demonstrated 
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the ability to fuse Pep-1 directly to a protein of interest.33-38 The groups were able to successfully 
express Pep-1-SOD1 and Pep-1-HSP which the groups demonstrated were sufficient to deliver 
into mammalian cells with effective results.33-38 Expressing Pep-1 as a fusion protein would 
circumvent the current stoichiometry problem as the ratio of Pep-1 to protein would be reduced 
to 1:1 rather than 16.8:1 with the non-fusion construct. Since the groups fused Pep-1 to the N-
terminus of their proteins, we chose to do the same and selected the N-terminus of the light 
chain. On first expression trial, however protein of two sizes were produced. The first elution 
after cation exchange yielded primarily a slightly larger protein than Fab7, suggesting that this 
could be the correct protein. However, the majority of the protein produced a size that was 
roughly the size of Fab 7 suggesting that it was truncated as shown in figure 4.18. Both fractions 
were tested in cell culture but the results were inconclusive owing to large errors but appeared to 
not demonstrate reduced viability (data not shown). 
Since the majority of the protein was not at the correct molecular weight, we learned that 
this was likely due to the N-terminus rule.54 The Pep-1 sequence begins with a lysine that is 
considered an unstable residue to begin a protein for overexpression in bacteria. While the initial 
protein actually starts with methionine and contains a secretion signal, this is cleaved in the cell 
after entry into the periplasm.55 It is likely that proteases were able to cleave at least some of the 
N-terminal residues. As such we verified the stabilizing residues in E. coli. Histidine is a 
stabilizing residue and Pep-1-SOD was expressed with a 6-his tag in the literature which is also 
used for purification on a nickel affinity column.33-38 We chose to express the same 6 his tag and 
a 12 his tag for possible future purification purposes. Additionally we attempted to clone in a 
single N-terminal glycine as a capping amino acid residue because it is a known stabilizer and its 
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small size is therefore less likely to inhibit the function of the fusion protein. Neither of the His-
tagged proteins were able to express however the glycine capped Pep-1 Fab 7 (GlyPep-1 Fab 7) 
was expressed in very high yield and expressed as a single band slightly larger than Fab 7 as 
demonstrated in figure 4.19. 
We then challenged GlyPep-1 Fab 7 at 50 µM vs mock treated control in two breast 
cancer cell lines, MDA-MB-231 and SK-BR-3. In both cases, cells that were treated showed 
about a 40% reduction in growth compared to the control when utilizing the MTS assay as 
shown in figure 4.20. Upon visual inspection of the cells, the remaining cells compared to the 
mock treated control appeared healthy and trypan blue was not able to stain the majority of cells 
in both treated and mock treated wells suggesting that the fusion protein produced a cytostatic 
rather than a cytotoxic effect. Gly-Pep-1 Fab 7 likely reduced cell growth rather than the killing 
of the cells as we expected for a Fab that would inhibit protein synthesis. 
Pep-1 on its own it is very toxic to cells at high concentrations, including at 50µM. 
However, when used as a fusion protein its toxicity may be partially or completely attenuated. 
Since 50 µM of Pep-1 alone caused drastic cytotoxic effects but 50 µM of fusion protein did not, 
this suggests that adding a protein directly fused to Pep-1 causes its properties to change. 
However, although we did see a growth reduction by the Pep-1 Fab 7 fusion protein, it is not 
clear if the cytostatic affect is caused by the Fab 7 portion of the molecule as we expected or by 
the Pep-1 portion. A control Fab that should not disrupt protein synthesis or other intracellular 
processes such as 4D5 fused to Pep-1 should be a good control. We therefore attempted to 
express Pep-1 4D5 fusion protein however it did not express. Because expression of recombinant 
foreign proteins can be challenging, we therefore continued to express a suitable control. We also 
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plan to use Fab as a control and expect that only Pep-1 Fab 7 is able to cause an effect by 
disrupting protein synthesis whereas we expect Fab 7 itself to not enter the cell and cause no 
effect while the control Fab with GlyPep-1 fusion should be able to enter the cell but not cause 
any effect. Continued efforts into expressing a control Fab in high yield is currently in progress. 
Conclusions 
Delivering therapeutic proteins into living tissues is a challenging task with emerging 
technologies gradually improving the efficacy of this process. Furthermore, specific targeting of 
cancer cells or other diseased cells relies heavily on their extracellular markers to distinguish 
them from normal surrounding healthy tissues.4 In an attempt to deliver a therapeutic Fab 
antibody, Fab 7, into breast cancer cells, we explored both non-specific and specific delivery 
options utilizing both commercial and novel methods. 
 We first attempted the expression of a bi-specific Fab antibody that is composed of Fab 7 
and Fab 4D5, an anti-Her 2 antibody that targets the Her-2 marker on breast cancer cells. 
However, in a basic microscopy study, we were unable to observe internalization of the control 
4D5 FITC-labeled Fab. After an interview with Christoph Spiess from Genentech, we learned 
that that antibody valency was important for internalization of the 4D5 antibody.47 A single 
valence Fab is not able to crosslink the receptors which are responsible for signaling to 
internalize the receptors via receptor mediated endocytosis and binding may be hindered. Since a 
4D5 Fab only has a valency of 1, this can explain why the 4D5 Fab control alone was not 
observed to stain Her-2 positive cancer cells. Genentech’s trastuzumab on the other hand is able 
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to both bind and internalize due to its dual valency where the antibody is expressed as an IgG 
molecule containing 2 Fabs. 
 We therefore prepared to improve the valency of 4D5 Fab and include the Fab 7 
therapeutic Fab by attaching individual Fabs to CuInS/Zns based quantum dots. These 
nanoparticles are ideal because they are bright, emit in the red to near infrared range which 
reduces auto-fluorescence background signals in tissue imaging studies, and permit the tethering 
of approximately 4-8 Fabs per QD.24 This model is more representative of a virus which would 
have multiple cell-binding antigens on its surface and thus should be able to cross-link multiple 
receptors on the cell surface to permit entry into the cell via receptor mediated endocytosis.21 
 The synthesis of the Copper Indium Sulfate based QDs was successful. More work 
however is needed to convert them from their suspension in organic solvents into an aqueous 
suspension and then further coating with streptavidin to attach to biotinylated Fabs. Cadmium 
sulfide based QDs with streptavidin coatings have been successfully synthesized and are 
commercially available.51 However, more work is needed to optimize streptavidin coating for 
CuInS/ZnS QDs. 
 Synthesizing the biotinylated Fabs for future attachment to QDs was made possible only 
after the successful synthesis of a free cysteine thiol on the Fabs. At first placing a free cysteine 
at the C-terminus of the heavy chain seemed ideal because it would be highly available for 
reaction and was unlikely to disrupt proper folding or create steric hindrance for antigen 
binding.39 However, this specific location was found to be “too” reactive permitting crosslinking 
of two identical Fabs, likely by enzymatic conjugation by the periplasmic enzymes of the 
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expression host 34B8 cells. Based on the literature, A121C was found to be available for 
reactivity but did not permit significant formation of Fab dimers.44 The A121C Fabs were able to 
be biotinylated by reacting to a maleimide moiety on a PEG-linked biotin tag. This permitted 
only one biotin per Fab and was shown to retain normal binding by the gel shift assay and as 
previously demonstrated by obtaining the KD value in the previous SPR experiment where the 
biotinylated Fab 7 was used to capture tRNAiMet. 
The commercial reagent Pep-1 was utilized according to the manufacturer’s instructions 
in an attempt to deliver Fab 7 directly into cancer cells. Since a positive experiment showing 
reduction in cell growth could not be repeated and required high amounts of reagent and high 
Pep-1 to protein ratio, this application was not practical. Furthermore, although the toxicity was 
reported to be low by manufacturer’s reference, this was not found to be the case in our lab.31 We 
thought this might be due to the use of untested cell lines, however when determining the 
toxicity of Pep-1 in HEK-293 cells reported to be almost non-toxic at 100 µM, we alternatively 
found this same concentration to be extremely toxic.31 Variance in cell culture conditions and 
reagents, change in cell line properties overtime, and batch to batch inconsistencies of chariot 
could all have been contributors to the variances observed in our laboratory compared to the 
publication. 
We therefore attempted to express Pep-1 as a fusion protein as it has already been 
demonstrated by several research groups, and would reduce the stoichiometry to a 1:1 ratio.33-38  
By cloning in the Pep-1 sequence at the N terminus of the light chain and with a glycine in front 
to abide by the N-terminal rule54, the protein was successfully expressed and was found to 
significantly reduce the viability of two different breast cancer cell lines at the tested 50 µM 
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concentration. However, more work is needed to express a control Fab in order to determine that 
the reduced viability is due to the Fab 7 portion of the fusion protein and not the N-terminal Pep-
1 sequence instead. 
The field of intracellular delivery of therapeutic proteins is challenging and currently 
limited. Given the current technology constraints, we were still able to prepare novel methods of 
delivery using nanoparticles and were able to confirm the findings of the original groups that it is 
possible to express Pep-1 as a fusion protein and obtain positive results when tested in cell 
culture. While more work is clearly needed, future developments of intracellular delivery 
technologies may help demonstrate the use of Fab 7 as a therapeutic molecule. 
Materials and Methods 
Synthesis of Fab 7 and 4D5 with a C-terminal Cysteine 
 Fab 7 and 4D5 phagemids containing stop codons were amplified and isolated from 34B8 
cells using a standard miniprep kit (Quiagen). The isolated phagemids were then transformed 
into electrocompetent CJ236 cells via electroporation. Cells were then inoculated in 1 mL 2YT 
containing ampicillin (100 ug/mL) and chloramphenicol (10 ug/mL) and incubated at 37°C 
shaking for about 6 hours until slightly cloudy. Log phage cells were infected with M13KO7 
helper phage (1010 pfu/mL) shaking for 10 min at 37°C then 300 µL were transferred into 30 
mL 2YT containing  ampicillin (100 ug/mL) and uridine (0.25 µg/mL) and was incubated at 
while shaking at 37°C for 19 hours. The culture was centrifuged for 10 min at 27 kg at 4°C and 
supernatant containing the phage was collected and precipitated with 20% w/v PEG, 2.5 M 
NaCl. Phage was pelleted by centrifuging for 10 min at 24 kg at 4°C, supernatant removed, and 
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then resuspended in 0.5 mL PBS. Single stranded DNA was then isolated from the phage 
according to the manufacturer’s instructions using the Qiagen Qiaprep Spin M13 kit #20004. 
 The Kunkel primer 
(TGTGACAAAACTCACACATGCTAGCGGCCCTCTGGTTCCGGT) was 5’ phosphorylated 
by incubating a mixture of 660 ng primer, 1 mM ATP, 5 mM DTT, 10 units T4 PolyNucleotide 
kinase in 1X TM buffer (0.5 M Tris pH 7.5, 0.1 M MgCl2) at 37°C for 1 hour. The 
phosphorylated primer (66 ng) was then annealed to the single stranded DNA Kunkel template (1 
µg) in 1X TM buffer by incubating at for 90°C for 1 minute followed by 50°C for 3 min. The 
template was then mixed with 0.4 mM ATP, 1 mM DTT, 6 mM DTT and 240 units T4 DNA 
ligase then spun down. Then 3 units of T7 DNA polymerase was added and incubated at 37°C 
for 1.5 hours. The Kunkel product was then PCA extracted twice, ethanol precipitated, and dried 
by high vacuum. The pellet was then re-dissolved in 5 µL sterile water and 1 µL was 
electroporated into 34B8 cells (40 µL of electrocompetent cells per electroporation) using 1.4 
kV. Electroporated cells were rescued in 960 mL of SOC media (100 µL total volume) and then 
incubated while shaking at 37°C for an hour. 100 µL was spread onto an LB/AMP plate and 
incubated overnight at 37°C. Colony PCR was used to evaluate the successful incorporation of 
Kunkel stop codons. Single colonies were added to a solution of Taq buffer, 2.5mM dNTPs, 0.05 
Units/µL Taq Polymerase, and 2.5 ng/ µL of both the forward (GGACGCATCGTGGCCC) and 
reverse (GAACCAGAGGGCCGCT) primers and the colony PCR program was executed. PCR 




 34B8 cells containing the Fab 7 or 4D5 C-terminal Cys phagemids were grown in 30 mL 
2YT supplemented with ampicillin (100 µg/mL) in 250 ml baffled flasks for 16 hours at 30°C 
with shaking, and then 5 mL of these overnight cells were inoculated into 500 ml CRAP media 
with ampicillin (100 µg/mL) and shaken for 24 hours at 30°C CRAP media was prepared fresh 
each time by dissolving 1.785 g (NH4)2SO4, 0.355 g NaCitrate•2H2O, 0.535 g KCl, 2.68 g yeast 
extract, and 2.68 g HyCase SF Casein in a total volume of 0.5 L, titrated to a pH of 7.3 then 
autoclaved in a 2.8 L baffled flask. After cooling, the media was completed by adding 55 mL 1 
M MOPS pH 7.3, 5.5 mL 50% w/v glucose, 3.5 mL 1M MgSO4, and 0.5 mL 100 mg/mL 
ampicillin. Fabs were purified on Protein A sepharose columns (Amersham) and Fab 7 was 
further purified on high S cation exchange columns for the in vitro translation assay. SDS-PAGE 
electrophoresis was used to analyze the purity of Fab proteins. 
Reduction of Fab 7 and 4D5 C-terminal Cys Dimers 
 About 21 µM of Fab7 Cys dimers and 4D5 Cys dimers were reduced with a range of 
TCEP concentrations (25 µM, 50 µM 100 µM 500 µM and 1mM) in 20 mM sodium acetate 
buffer pH 5.0 for 10 minutes at RT. 
 About 21 µM of Fab7 Cys dimers and 4D5 Cys dimers were reduced with a range of 2-
MEA concentrations ( 25 µM, 50 µM 100 µM 500 µM and 1mM) in PBS-EDTA and 20 mM 
sodium acetate buffer pH 5.0 for for 1.5 hours at 37°C. The 4D5 Cys dimers were additionally 
treated with additional 2-MEA concentrations for a finer tuned range (100 µM, 200 µM, 300 
µM, 400 µM and 500 µM) using the same conditions as above. SDS-PAGE electrophoresis was 




Synthesis of Fab 7 and 4D5 A121C 
 Fab 7 and 4D5 A121C Fabs were synthesized as described for the Synthesis of Fab 7 and 
4D5 C-terminal Cys utilizing the same single-stranded kunkel template previously generated. 
The kunkel primer was changed to 
(ACCCTGGTCACCGTCTCCTCGTGCTCCACCAAGGGCCCATCGGTC), the forward 
colony PCR primer remained the same, and the reverse colony PCR primer was changed to 
(GGCCCTTGGTGGAGC) to verify the A121C point mutation. 
Synthesis of the Bi-specific Fab 
 Three different attempts were made to optimize Bi-specific Fabs. SM(PEG)4 NHS-PEG-
Maleimide Crosslinker (100mg) MW = 513.5 (Thermo # 22104) was dissolved by adding dry 
DSMO via syringe (680 µL) and heating for 37°C for 15 minutes to fully dissolve (250mM). For 
the first reaction, the linker (1mM) and Fab 4D5 (100 µM) were mixed (200 µL total in PBS) 
shaking for 30 min at RT. The entire volume of the reaction was added to a Zeba Spin Desalting 
Column (Thermo # 89890) and then 40 µL of PBS was added as a stacker. The Column was 
spun for 2 mins at 1000 x g in a 15 mL conical tube. The effluent was then transferred to a 
microcentrifuge tube and 200 µL of 100 µM of Fab 7 A121C was reacted with the 4D5 Fab 
linker conjugate containing a free maleimide reacting group in the effluent for 30 mins shaking 
at RT. 
 For the second reaction the linker was thawed at RT and then at 37°C for 25 minutes. The 
tube was centrifuged to remove precipitant for 30 sec at top speed* then the supernatant was 
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transferred to a new microcentrifuge tube. The reaction was performed in the same way as the 
first reaction except for the additional 15 mins incubation at RT following the addition of 2 µL of 
1M Tris pH 7.5 to quench the reaction after the 30 min reaction between the linker and 4D5 Fab. 
Additionally, the reaction was centrifuged at top speed after using the Zebra Spin Desalting 
Column to remove precipitant and supernatant was transferred to a new microcentrifuge tube. 
Fab 7 A121C was then reacted with 4D5 Fab linker conjugate containing the free maleimide 
group at a molar ratio of 1.5 to 1 (The first reaction was 1:1) for 30 mins shaking at RT. 
The third reaction was performed the same as the first reaction but using 30% less of the 
linker (0.56 µL), and using 1.3 to 1 molar ratio of Fab 7 A121C to Fab 4D5. The final product 
was centrifuged at top speed to remove any precipitant and the supernatant was transferred to a 
new microcentrifuge tube. The three reactions (2 µL per reaction) were incubated with  non-
reducing dye in PBS (total 6 µL) for 5 minutes at 95°C and were then imaged by 5% SDS-PAGE 
electrophoresis for 40 mins at 120V and 10% SDS-PAGE electrophoresis for 60 mins at 120V to 
monitor the reactions. 
Biotinylation of Fab 7 and 4D5 A121C and Bead Pull-Down Assay 
 EZ-Link Maleimide-PEG2-Biotin (5mg) MW= 525.26 (Thermo #21901) was dissolved in 
DSMO (50 mM). The biotin tag (1mM) and 4D5 A121C (1mg, 2mg/mL ~51µM ) were mixed in 
PBS pH 7.2 (450 µL total) shaking at RT for 3 hours. The protein was then dialyzed into PBS 
overnight. Similarly the biotin tag (1mM) and Fab 7 A121C (1mg, 2mg/mL ~ 42 µM) were 




 For both biotin-tagged proteins, 250 μL of streptavidin beads (Promega #Z5482) were 
washed twice with PBS and re-suspended in 250 µL PBS and then aliquoted into tubes with the 
following volumes: 3, 6, 15, 30, 60, 120 μL and then PBS was removed. Then 4 µL of the 
dialyzed biotin-tagged protein was diluted with 76 µL of PBS and 10 µL of the diluted biotin-
tagged protein (~25 pmol) was added to the beads, shaking for 15 minutes at RT. After 
incuvation, 8 μL of the supernatant was mixed with 2 µL of non-reducing dye and incubated for 
5 mins at 95°C and was run on a 10% SDS-PAGE gel (60 min 120V). Biotin tagged Fabs and 
unused Biotin linker was stored at -20°C 
Synthesis of Copper Indium Sulfide Quantum Dots 
Copper Indium Sulfate Core QD synthesis 
Copper Iodide (95.9 mg, 0.5 mmol) and Indium acetate (146.2 mg, 0.5 mmol) were added 
to the 3-neck flask. DTT (5mL) was added via serological pipette. The reaction was heated to 
100°C stirring, degassing with argon 3 times. It took about an hour for the reaction (some 
particles in the solution) to heat up to 100°C stirring (actual temp about 92°C). This was allowed 
to proceed for 30 min. The reaction was then heated to 230°C for 20 min (but reached an actual 
temperature of about 190°C) which changed color from a yellow orange solution to a 
strawberry/cherry red solution becoming darker with time. It glowed under the standard 
fluorescent and UV lighting. 
Zinc Sulfide Shell Synthesis 
DDT (1 mL) and 1-octadecane (4 mL) were used to dissolve Zn Stearate (4 mmol, 
2.528g) heating at 190°C stirring. This solution was added to the core QDs into the 3 neck flask, 
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drop wise via syringe to yield an orange colored solution. The reaction was stirred for 70 min at 
240°C (actual about 190°C) which could also glow under UV. The reaction was cooled to 45°C 
and then washed 1 time with 95% EtOH and then twice with chloroform: EtOH (1:1) 
centrifuging to clean. The QDs were then dissolved in chloroform. 
FITC Conjugation of 4D5 Fabs 
FITC was dissolved in DMSO to create a 25 mM stock solution (~10 mg/mL). For each 
reaction, the FITC (1 mM) was then reacted with the 4D5-Fab (2 mg/mL ~42 µM) in a total of 
250 µL carbonate buffer pH 9.5 (160 mM Na2CO3, 333 mM NaHCO3) by shaking for 1 hour 
shaking at RT in the dark. The FITC-conjugated Fabs were then dialyzed in PBS remove 
unbound FITC and were stored at -80°C to prevent aggregation. Protein concentrations were 
determined by the formula [A280 protein – (Amax * CF)] / ε protein  * dilution factor where CF 
(correction factor) = 0.3 for FITC and Amax (absorbance max of dye) is 494 nm for FITC. 
Average number of dye molecules per protein was calculated using the formula Amax / (ε’ * 
protein conc in M) * dilution factor where ε’ = 68,000 M-1 cm-1 for FITC. 
Cell Culture 
MDA-MB-231, SK-BR-3, L3.6pL and HEK-293 cells were maintained in high glucose 
DMEM supplemented with 10% FBS and Penicillin (100 IU/mL) / Streptomycin (100µg/mL) at 
37°C in an environment with 5% CO2. Cells were subcultured in a ratio of 1:3 approximately 
every 3-5 days. 
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Slide Preparation and Microscopy 
 L3.6pL cells and SK-BR-3 cells were grown on poly-D-lysine coated (0.05mg/mL) cover 
slips (22 mm², 0.17mm thickness) in complete media for 24-48 hours or until at least 50% 
confluency was achieved in 2.5 cm dishes. Cells were then washed 3 times with PBS and then 
fixed with 4% methanol-free formaldehyde for 10 minutes. The formaldehyde was then decanted 
and the fixed cells were washed with PBS 3 times. The fixed cells were treated with the FITC-
4D5 Fab at various concentrations overnight and washed 3 times with PBS. The coverslips were 
then partially dried, treated with ProLong(R) Gold Antifade mounting reagent (Life technologies 
#36930), mounted on slides and allowed to cure for 24 hours before imaging. Coverslips were 
sealed with nail polish and slides stored at 4°C for long-term storage. Slides were then imaged 
using a 488 laser excitation source with a FITC emission filter on an Olympus Fv300 laser 
scanning confocal microscope. 
MTS Assay to Determine Pep-1 Delivery into Cancer Cells 
MDA-MB-231 cells were seeded at 5000 cells /well and SK-BR-3 cells were seeded at 
4000 cells /well in complete media [DMEM supplemented with 10% FBS and Penicillin (100 
IU/mL) / Streptomycin (100µg/mL)]. After 48 hours, the media was removed and cells were 
washed once with PBS. Cells were then treated with 20 µL of a mixture of Pep-1 and Fab 7 or 
Pep-1 only or mock PBS pre-incubated for half an hour at RT, and then 80 µL of serum free 
media was added. Cells were incubated for 2 hours and then 100 µL of complete media was 
added to the sample and mock treated cells to quench the treatment and replenish the nutrients. 
After 20 hours of incubation, 40 µL of the MTS reagent was added to each treated well and the 
116 
 
absorbance at λ490 nm of the plates was read after incubating 4 hours later on a standard plate 
reader. 
MTS Assay to Determine Pep-1 Toxicity Control Using HEK-293 Cells 
 HEK293 cells were seeded at 3000 cells / well in complete media. After 48 hours, the 
media was removed and cells were washed once with PBS. Cells were then treated with 10 µM, 
25 µM  50 µM  and 100 µM or mock PBS in a total of 100 µL of serum-free DMEM added after 
addition of pep-1 or mock control. After 4 hours, 100 µL of complete media was added to the 
peptide and mock treated cells. After 20 hours, 40 µL of the MTS reagent was added to each 
treated well and the absorbance at λ490 nm of the plates was read 4 hours later on a standard 
plate reader. Cells were incubated at 37°C in a CO2 incubator during all incubation steps. 
Synthesis of Pep-1 Fab 7 Fusion Protein Constructs 
Pep-1 Fab 7 Fabs were synthesized as described for the Synthesis of Fab 7 and 4D5 End 
Cys utilizing the same single-stranded Kunkel template previously generated. The Kunkel primer 
was changed to 
(GCTACAAATGCCTATGCAAAAGAAACCTGGTGGGAAACCTGGTGGACCGAATGGTC
TCAGCCGAAAAAAAAACGTAAAGTGTCCGATATCCAGATGACC), the forward colony 
PCR primer (CTGTCATAAAGTTGTCACGG), and the reverse colony PCR primer 
(TTTCGGCTGAGACCATTC) were used to  verify the additon of the Pep-1 sequence to the N 
terminus of the Fab light chain. Expression of the Kunkel product in 34B8 cells yielded two 
fractions of protein as observed by UV-vis spectroscopy and SDS-PAGE electrophoresis (F1 and 
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F2 respectively), with the first eluted fraction (F1) after cation exchange as the major product 
which appeared to be a truncated product of the desired construct. 
 To stabilize the protein due to the N-terminal rule where Pep-1 begins with an unstable 
lysine, the protein was capped with the stabilizing glycine residue. The Pep-1 Fab 7 Fusion 
plasmid was isolated from 34B8 cells by standard miniprep and transformed into CJ236 cells and 
amplified to produce a single stranded DNA kunkel template as described above. The kunkel 
primer was changed to (GCTACAAATGCCTATGCAGGCAAAGAAACCTGGTGGGAA) and 
colony PCR was used to verify the point mutation with the forward primer 
(CTGTCATAAAGTTGTCACGG) and the reverse primer (CCCACCAGGTTTCTTTGC). The 
resulting protein expressed in 34B8 cells exhibited very high yield after Protein A column and 
cation exchange purification as verified by UV-vis spectroscopy and SDS-PAGE. 
MTS Assay of GlyPep-1 Fab 7 Treated Cancer Cells 
 MDA-MB-231 cells were seeded at 5000 cells /well and SK-BR-3 cells were seeded at 
4000 cells /well in complete media [DMEM supplemented with 10% FBS and Penicillin (100 
IU/mL) / Streptomycin (100µg/mL)]. After 48 hours, the media was removed and cells were 
washed once with PBS. Cells were then treated with 20 µL of GlyPep-1 Fab 7 or mock PBS and 
then 80 µL serum free media for a total concentration of 50 µM. After incubating for 4 hours, 
100 µL of complete media was added to the protein and mock treated cells. After incubating for 
20 hours, 40 µL of the MTS reagent was added to each treated well and the absorbance at λ490 
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Figure 4.1. Antibodies can bind to antigens such as cell surface receptors and a.) block natural 
ligand binding or b.) can be conjugated to toxins and bind cell surface receptors to target the 




Figure 4.2. When ligands binds to their receptors, signaling may occur that permits receptor-
mediated endocytosis (RME) of the ligand-bound receptors. RME can be used to internalize 




Figure 4.3. A virus uses multiple antigens simultaneously to bind to multiple receptors on the 




Figure 4.4. Fab 7 Cys fractions (20µL) after cation exchange chromatography. L is the protein 




Figure 4.5. Reduction of 4D5 Cys dimers with the reducing agents TCEP and 2-MEA. a.) Lane 
1: 4D5 Cys; Lane 2: 4D5, Lane 3: 4D5 Cys + 25 µM TCEP; Lane 4: 4D5 Cys + 50 µM TCEP; 
Lane 5: 4D5 Cys + 100 µM TCEP; Lane 6: 4D5 Cys + 500 µM TCEP; Lane 7: 4D5 Cys + 1mM 
TCEP. b.) Lane 1: 4D5 Cys; Lane 2: 4D5, Lane 3: 4D5 Cys + 25 µM 2-MEA; Lane 4: 4D5 Cys 
+ 50 µM 2-MEA; Lane 5: 4D5 Cys + 100 µM 2-MEA; Lane 6: 4D5 Cys + 500 µM 2-MEA; 
Lane 7: 4D5 Cys + 1mM 2-MEA. c.) Lane 1: 20.5 µM 4D5 Cys; Lane 2: 4D5, Lane 3: Cys + 
100 µM 2-MEA; Lane 4: 4D5 Cys + 200 µM 2-MEA; Lane 5: 4D5 Cys + 400 µM 2-MEA; Lane 
6: 4D5 Cys + 500 µM 2-MEA; Lane 7: 4D5 Cys + 1mM 2-MEA. 10% SDS-PAGE 
electrophoresis was performed for 70 min at 100V and stained with coomassie blue dye. About 
20.5 µg of sample was loaded in each well except for the ladder (L) which was used according to 




Figure 4.6. Schematic showing possibilities of Fab Cys constructs produced by 34B8 cells or 




Figure 4.7. Verifying the expression of A121C Fabs using 10% SDS-PAGE. Lane 1: 4D5 




Figure 4.8. Construction of the bi-specific Fab. The NHS group on the SM(PEG)4 Maleimide 
NHS Linker is first attacked by a random amine group on 4D5 Fab. Then the free cysteine 




Figure 4.9. a.) Comparison of the bi-specific Fab synthesize by 3 different reaction conditions 
on 5% SDS-PAGE for 40 minutes. L: Protein precision ladder; Lane 1: reaction 1; Lane 2: 
reaction 2; Lane 3: reaction 3; Lane 4 Fab 7 A121C; Lane 5: 4D5. b.) Cartoon of synthesized bi-





Figure 4.10. a.) Biotinylation of A121C Fabs by conjugation to SM(PEG)2 Maleimide Biotin 
Linker. B.) Biotinylated proteins can bind to streptavidin or neutravidin coated surfaces such as 




Figure 4.11. 10% SDS-PAGE electrophoresis showing the remainder of biotinylated Fab left in 
the supernatant during the Bead pull-down assay L: Protein precision ladder; Lane 1: 0 beads; 
Lane 2: 3 µL beads; Lane 3: 6 µL beads; Lane 4: 15 µL beads; Lane 5: 30 µL beads; Lane 6: 60 




Figure 4.12. a.) FITC molecule conjugation to a Fab b.)10% SDS-PAGE gel showing successful 
FITC-conjugation of 4D5 Fabs imaged under UV excitation. Actual emission is green light. Lane 














Figure 4.15. CuInS / ZnS Quantum Dots a.) as observed under visible light and b.) as observed 




Figure 4.16. Treatment of the HEK 293 cell line with Pep-1 (Chariot™) at various 





Figure 4.17. MTS assay showing the viability of cells treated with Fab 7 Chariot complexes at 
different concentrations. Samples were performed in douplicate. a.) The percent viability of SK-
BR-3 breast cancer cells normalized to the mock (PBS) treated control. b.) Image of the actual 




Figure 4.18. After cation exchange chromatography, GlyPep-1 Fab 7 eluted as two major 
products, one at the expected size and one at a smaller size indicating truncation. L: Protein 





Figure 4.19. A 10% SDS-PAGE gel showing two fractions (A2 and A3) of GlyPep-1 Fab 7 after 
affinity chromatography at their expected molecular weight compared to the Fab 7 control and 




Figure 4.20. The treatment of either MDA-MB-231 or SK-BR-3 breast cancer cells with 50 µM 
GlyPep-1 Fab 7 resulted in about a 40% reduction in viability compared to the mock treated 
control using the MTS assay. 
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CHAPTER 5: CONCLUSIONS 
 We now know that the vast majority of the human genome is indeed transcribed but does 
not code for proteins.1 However, which of these transcripts have function, and how they function 
is largely unknown. Many of these transcripts are transcribed as long non-coding RNAs 
(lncRNAs) and are predicted to have tertiary structure and perform regulatory functions that 
when disrupted likely lead to human disease as has already been demonstrated with several non-
coding (ncRNAs).2-7 They also likely have diversified roles and behave much like proteins in 
their ability to form distinct structural domains and carry out various tasks when interacting with 
macromolecules such as other RNAs, DNA and proteins.7-10 While the currently known structure 
and function of these non-coding transcripts is still severely limited, new tools are being 
developed to move the ncRNA field forward.8 
 Compared to most proteins, RNAs are relatively unstable mainly because they are highly 
susceptible to RNase activity either introduced from improper handling or sample preparation by 
which the RNA is isolated from cell lysates that are rich in nucleases until purified.11 To reduce 
nuclease degradation of RNAs and produce high yields of any target RNA for study, RNAs can 
be in vitro transcribed.11 This method is typically the preferred method of acquiring high 
quantities of a specific RNA since only about 5% of total extracted RNAs are the mRNAs and 
non-coding transcripts while the other 95% are ribosomal RNAs and the tRNAs.11,12 Indeed, the 
ability to in vitro transcribe RNA has permitted growth in the field where high quantities of 
highly pure RNAs are absolutely necessary.11 In vitro transcribed tRNAs for example have been 
used to study the kinetic activity of several aminoacyl-tRNA synthetase (aaRS) enzymes.13 
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Using this same technology, we were able to produce highly purified human initiator tRNA 
(tRNAiMet) and human elongator tRNA (tRNAiMet). This is significantly important as yeast 
tRNAiMet is extremely difficult to isolate and human tRNAiMet has not been reported in 
significant yields to the best of our knowledge.14,15 
Previously, our group developed chaperone-assisted RNA chromatography (CARC) to 
address the difficulty in obtaining RNA crystal structures which also took advantage of in vitro 
transcribed RNAs.16 RNAs are difficult to crystalize for several reasons including the above 
mentioned instability primarily due to nuclease activity. Furthermore, the flexibility of RNA 
structures and highly negatively charged phosphate backbone make crystalizing them very 
challenging. Since the binding partners of many structured RNAs are unknown, and these 
binding partners may impart stability when bound, raising antibodies in the form of Fabs that can 
bind with high affinity was a key step in enhancing RNA crystallization.16 Using the phage 
display technique to identify high affinity Fabs, a method necessary to bypass RNA degradation 
using the classic animal systems, it was demonstrated that this method is a viable solution for 
generating Fab antibodies against any structured RNA.17 As such, the RNA field has moved 
forward once again and with an improved crystallization method. 
While Fabs have been successfully generated against several structured RNAs and crystal 
structures have resulted, the Fabs were not designed to perform any additional function let alone 
have potential therapeutic value.16,18 Furthermore, all previously isolated Fabs were generated 
against RNAs of single-celled organisms. Prior to beginning the work that led to this dissertation, 
there were no peer-reviewed publications that addressed the identification of Fabs that could 
bind to human structured RNAs. Only recently, one group successfully produced a Fab against a 
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single oncogenic human RNA, even referencing our own groups work, but did not demonstrate 
any potential ability to behave as a therapeutic antibody.19 In our work, not only did we confirm 
the ability to generate a Fab, Fab 7, that can bind to an oncogenic structured human RNA, 
tRNAiMet, we also demonstrated its ability to reduce protein expression in vitro, disrupt 
methionyl-tRNA synthetase (MARS) from charging tRNAiMet in vitro, and showed potential 
efficacy of reducing cell viability in cell culture presumably by disrupting protein synthesis 
Fab 7 itself was generated by using the phage display technique20,21, however we initially 
were not able to identify any antibodies that successfully bound to tRNAiMet from the YSGRX 
phage library. Previously, our group developed the YSGR Min library that was designed to be 
optimized for RNA-binding antibodies whereas YSGRX was optimized for proteins.17 Since 
YSGR Min was able to generate Fab 7, we were able to verify the group’s previous work that 
YSGR Min could successfully produce successful RNA binding Fabs, and may very well be 
improved over YSGRX for binding RNAs as intended since we were unsuccessful at identifying 
a Fab that could bind to tRNAiMet using the YSGRX library. 
In order to study the interactions between proteins, scientists have developed a repertoire 
of antibodies that bind to the majority of proteins. Indeed, it is difficult to find a protein that 
doesn’t have an antibody raised against it for sale at this time. Antibodies are important for 
molecular biology techniques such as ELISA, affinity chromatography, and western blotting.22,23 
However these techniques must be modified accordingly for use with RNAs. Western blotting is 
used to identify the expression of proteins and their binding partners, and as verification of 




In order to determine the cross-reactivity of our Fab 7 antibody, we needed to modify the 
western blot technique so that it would be suitable for use with RNA. We therefore determined 
and optimized the parameters including membrane selection, buffers, and blocking reagents that 
would be suitable for use with RNA instead of proteins. As such, we successfully developed the 
“Northwestern blot” and could clearly distinguish between tRNAiMet and tRNAeMet with high 
resolution. We chose a positively charged membrane (Hybond N+) in order to capture the RNA 
where nitrocellulose does not attract RNA as these results were already demonstrated during the 
filter binding assay. Nuclease-free blocking agents were necessary to prevent degradation of the 
RNA. Additionally, we learned that when using a positively charged membrane, a negatively 
charged antibody or antibody substitute is not compatible. This was demonstrated by protein A-
HRP which caused electrostatic binding to the membrane thus creating too much background 
noise and no blocking agent was sufficiently strong enough to be able to prevent this from 
occurring. Using a secondary antibody with a neutral isoelectric point was able to solve this 
major hurdle. As such, the Northwestern blotting technique is suitable to detect cross-reactivity 
of any Fab generated against any structured RNA. 
 The result of our Northwestern blot when using Fab 7 as a primary antibody to identify 
cross-reactivity of Fab 7 with other RNAs in total extracted RNA samples lead to far more new 
questions than answers. We were unable to detect tRNAiMet in the expected location running 
purified tRNAiMet as a control on the same gel, even though when staining a duplicate gel, 
tRNAs as a whole migrated to the expected location. To complicate things further, we identified 
a faint band above the expected location of tRNAiMet and a high signal coming from the top well 
where only the large ribosomal RNAs are expected to come. One explanation for the faint signal 
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is the presence of pre-tRNAiMet which would be expected to come at about this location. As for 
the top signal, either Fab 7 cross-reacts with ribosomal RNAs or alternatively, it may be possible 
that all of the mature tRNAiMet is associated with the ribosome upon purification and could 
possibly be bound or entangled in the large subunit. 
Although in vitro transcribed RNAs are known to well represent their naturally occurring 
counterparts, including being able to be charged by their corresponding aaRS enzymes, in vitro 
transcribed RNAs are lacking in the modified bases that occur naturally in native RNAs.13,24 
Native tRNAiMet for example has 8 base modifications which are mainly involved in excluding 
tRNAiMet from behaving as an elongator tRNA.24-26 Nonetheless, since antibodies are very 
specific, it is possible that even the addition of a single methyl group could compromise Fab 
binding to native tRNAiMet. This is homologous to the issue of raising antibodies against 
recombinant RNAs from bacteria. Animal proteins are often “decorated” with carbohydrate tags, 
phosphorylated, and modified in other ways that can be specific at the organismal level.27 Since 
E. coli and yeast do not have the necessary enzymes to produce the same post translational 
modifications that mammalian cells do, raising antibodies against their recombinant proteins may 
not be successful. Interesting, modified yeast strains have been developed recently that can 
overcome glycosylation hurdles.28 
However our preliminary northern blot did show a signal in the well as was also observed 
in our Northwestern blot which supports the “tRNAiMet trapped in the ribosome” hypothesis. 
Further controls are needed to determine if Fab 7 can indeed bind native tRNAiMet. If it cannot, 
then we have learned that raising an antibody against in vitro transcribed RNA which lacks 
modifications may not be suitable for identifying therapeutic antibodies. On the other hand if it 
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does bind to native tRNAiMet trapped in the ribosomal RNA, then alternatively we have learned 
that RNA purification does not segregate all RNAs by size even under denaturing conditions. 
Regardless of Fab 7’s actual target, it was shown to inhibit protein expression in vitro and 
cell viability in cell culture when expressed as the GlyPep-1 Fab 7 fusion protein. Most RNAs 
are intracellular targets so it is important that therapeutic Fabs be able to be internalized by the 
target cells.  In our work, we prepared for and explored several delivery options both specific and 
non-specific. Since many aberrant proteins are also potential internal targets for antibody-based 
therapy, it is important that this delivery issue be solved for all intracellular targets. The GlyPep-
1 Fab 7 fusion construct was successful in reducing cell growth. Although more controls are 
needed to verify that this effect is due to Fab 7 rather than the Pep-1 portion of the molecule, the 
results are promising. When using Gly-Pep1 Fab 7 on cancer cells, a cytostatic effects was 
observed, however using the same molar ratio of Pep-1 by itself caused a drastic cytotoxic effect 
instead. 
Therapeutic antibodies raised against proteins have been marketed under FDA approval 
in the United States since the first was introduced in 1986.29,30 Unlike with proteins, it is unlikely 
you will find antibodies for sale as therapeutics designed to target RNAs in the immediate future. 
Our research which is a continuation of the combined efforts of the RNA scientific community, 
however, has taken us one step closer towards making this goal a future reality. At the time of 
this writing, we are one of only two groups that have successfully generated Fabs binding to 
oncogenic RNAs, and we are the first group to the best of our knowledge to produce an RNA-
binding Fab with a function and potential therapeutic value.19 Our group will continue to 
evaluate Fab 7 to determine its binding properties and its delivery into cancer cells. We also plan 
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to use techniques such as RNA footprinting to help elucidate where Fab 7 binds to in vitro 
transcribed tRNAiMet and to help us understand structural motifs on RNAs that are good 
antigens. 
Other future directions include using RNA-binding Fabs as immunoprecipitation tools. 
One of the common ways of learning which proteins interact with other proteins is by 
immunoprecipitation. An antibody binds a known protein and the other proteins bound to it co-
precipitate allowing for discovery of binding partners. RNA-binding antibodies could similarly 
be used to co-precipitate both RNAs and proteins bound to target RNAs. Furthermore, we will 
continue to identify Fabs that can bind to other structured RNAs involved in human disease. 
Already, our group has cloned and transcribed the 5’ domain of HOTAIR that is responsible for 
binding PRC2.31 If successful at making the antibody and it can block PRC2 binding, then 
delivery of such a Fab into cancer cells that overexpress PRC2 could prevent tumor growth and 
block metastasis. As more structured RNAs involved in human disease are discovered, our group 
is prepared to make antibodies against them that will become both valuable molecular biology 
tools and future therapeutic biologics.  
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